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HIV-1 is a virus that afects over 35 milion individuals around the world, and yet despite 
present treatments, there remains a need for a cure. A curent cure tactic widely 
researched is the “shock and kil” strategy, where cART-treated HIV-positive individuals 
would be given latency reactivating agents (LRAs) to induce HIV-1 production from 
latently-infected CD4+ T cels, alowing for the CD8+ T cel response to eliminate the 
latent reservoir. Here, I examined the capabilities of the CD8+ T cel response from HIV-
positive individuals to eliminate macrophages, another cel type infected by HIV-1, and 
reactivated latently-infected primary CD4+ T cels, both reactivated with PMA and 
ionomycin and with LRAs. Both CD4+ and CD8+ T cels from elite suppressors, HIV-
positive individuals with viral loads of less than 50 copies per mililiter of blood, were 
capable of suppressing virus production from HIV-infected monocyte-derived 
macrophages, with the CD8+ T cels actualy kiling the infected cels. As to the latently-
infected CD4+ T cels, CD8+ T cels from chronic progressors were not consistently 
capable of eliminating the infected cels upon reactivation, although those from two of 
four viremic controlers were when PMA and ionomycin were used for stimulation. 
Treatment with LRAs such as bryostatin and romidepsin both alone and in combination 
significantly inhibited the CD8+ T cel response to HIV-1, with the mechanism for 
bryostatin inhibition being an increase in cel death, downregulation of CD3, and 
upregulation of exhaustion markers. Despite that the elite suppressor CD8+ T cel 
response was capable of inhibiting HIV-1 infection of macrophages and that the response 
of some viremic controlers and chronic progressors can do so for latently-infected CD4+ 
T cels, there remains a need for some sort of immunologic boost for the average 
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individual with HIV-1 infection. Worse, some LRAs and combinations of LRAs decrease 
the ability of the CD8+ T cel response to eliminate infected CD4+ T cels. Therefore, 
any given LRA or combination of LRAs should be examined for their efects upon the 
adaptive immune response prior to use in clinical investigations of HIV-1 cure strategies. 
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I. INTRODUCTION 
 
 HIV-1 is a retrovirus that afects over 35 milion people worldwide (1). Upon 
HIV-1 infection most individuals experience acute viremia accompanied by a decline in 
CD4+ T cels (HIV pathogenesis reviewed in 2). After the adaptive immune system and 
specificaly the CD8+ T cel response is primed, the viremia declines to what is known as 
the viral set point, which is generaly between 10,000-100,000 copies of HIV RNA per 
mL of blood, and the CD4+T cel count recovers (3). In the absence of therapy, an 
individual’s immune systems wil eventualy lose what control it had, and the viremia 
wil begin to increase as the CD4+ T cel count decreases. At a CD4+ T cel count of 200, 
an individual would be diagnosed with acquired immunodeficiency syndrome (AIDS) 
and, with the continuing decrease in CD4+ T cels and absence of therapy, would be 
susceptible to opportunistic infections and eventualy die (4). The use of antiretroviral 
therapy in HIV-positive individuals is capable of suppressing viremia to levels below the 
limit of detection by clinical assays and increases life expectancy to similar levels as 
those who are HIV-negative (5). However, despite the existence of combined 
antiretroviral therapy (cART, formerly known as HAART), both a cure and a vaccine 
remain elusive. 
 Each HIV-1 virion contains two copies of the positive single-stranded RNA viral 
genome within the capsid (6). The genome of HIV-1 encodes nine genes: the structural 
proteins of gag, pol, and env; the accessory proteins vif, vpu, and vpr; and the early 
expressed proteins tat, rev, and nef (7). The life cycle of the virus begins when the viral 
envelope fuses with the celular membrane of a CD4+ T cel or a macrophage (8). HIV-1 
uses the primary receptor CD4 and either CCR5 or CXCR4, the preference for which of 
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the two coreceptors determines viral tropism (9-11). Once the viral capsid is within the 
cel, the viral genome undergoes reverse transcription and is shutled as DNA into the 
nucleus. Inside the nucleus, the viral DNA is integrated into the host genome (12) and 
wil remain there as a provirus until the appropriate transcription factors induce 
transcription and translation of the fuly spliced transcript (13-15). Tat and Rev, two of 
the three early expressed proteins from the fuly spliced transcript, alow for increased 
transcription of the HIV-1 genome as wel as the alternative splice variants that encode 
for the rest of the genes (13-15). Once al of the viral proteins are available, they form 
new virions and are released from the target cel, usualy inducing cel death (16). 
 Reverse transcription is highly eror-prone process, introducing mutations into the 
various proteins of HIV-1 and alowing the virus to evade the adaptive immune response 
(17-18). The variable regions of env in particular are highly prone to mutation, making 
the development of an antibody vaccine that covers even a single subtype of HIV-1 very 
dificult (19). That said, multiple antibody-based vaccine candidates have been suggested 
in recent years and have shown great promise (20-21), but the CMV-based SIV vaccine 
tested in the rhesus macaques induced a CD8+ T cel response capable of eliminating SIV 
infection to the point that no DNA was detected in multiple tissues (22). 
 While no sterilizing cure owing to the immune response has been seen in humans, 
CD8+ T cel-mediated control of HIV-1 has been observed in HIV-positive long-term 
non-progressors (LTNPs) for decades (23-24). Although these individuals are HIV-
positive, they do not progress to AIDS in the absence of cART. Elite suppressors (ES) are 
a related group of HIV-positive non-progressors who have a viral load of less than 50 
copies of HIV-1 per mililiter of blood in the absence of antiretroviral therapy (25). 
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Overal, ES tend to have qualitatively superior CD8+ T cel responses to HIV-infected 
CD4+ T cels: the ability of the CD8+ T cels to kil via granzyme B or perforin as wel 
as the cels’ ability to produce antiviral cytokines such as IFN-gamma and TNF-alpha are 
extensively documented to be superior in ES as compared to the average chronic 
progressors (26-31). The immunologic control exhibited by the ES in their immune 
responses may be considered a model for an efective immune response to HIV-1 needed 
for a functional cure (32). 
 The need for an efective adaptive immune response is not solely limited to the 
vaccine efort. HIV-1 preferentialy infects activated CD4+ T cels, but owing to T cel 
biology, an infected CD4+ T cel may return to a resting state prior to virus-mediated cel 
death but folowing integration of the provirus (reviewed in 33). Normaly, once CD4+ T 
cels see their cognate antigen, they become activated and perform their efector 
functions. Most of these cels die after the infection associated with the antigen is cleared, 
but not al of the activated cels die and some instead return to a resting state thus 
preserving immunologic memory. Many of the transcription factors associated with T 
cel activation (such as NFkB and NFAT) are in fact necessary for the transcription of 
HIV-1 provirus (34-37), and when an infected T cel returns to a resting state, these 
transcription factors are sequestered away from the nucleus, rendering HIV-1 more or 
less transcriptionaly silent. Without production of antigen, these infected yet 
transcriptionaly silent cels unable to be detected by the cytotoxic T lymphocyte 
response (38). Antiretroviral therapy likewise has no efect on these CD4+ T cels as the 
antiviral drugs target only the replication steps in the viral life cycle. These infected 
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CD4+ T cels make up what is termed the latent reservoir and are efectively a major 
reason that cART alone cannot cure individuals (39). 
 Curent eforts to eliminate the latent reservoir are focused on a strategy termed 
“shock and kil” (reviewed in 40 and 41). In this strategy, a patient would theoreticaly be 
treated with latency reactivating agents (LRAs), drugs that specificaly induce HIV-1 
transcription but not global T cel activation, to reactivate the provirus present in resting 
CD4+ T cels (40-41). Once HIV-1 transcription initiates, antigen is then produced, 
alowing for the CD8+ T cel response to identify and eliminate the infected cels. Strong 
candidates for LRAs include HDAC inhibitors and PKC agonists (42-45). In vitro data 
with latently infected CD4+ T cels from patients have shown that while some LRAs 
such as romidepsin, panobinostat, and bryostatin-1 are capable of inducing production of 
HIV mRNA, combinations of LRAs from separate drug classes are likely to be necessary 
(46). That said, there have been conflicting reports regarding the efects of the HDAC 
inhibitors upon the adaptive immune system (47-48). The archived proviruses of 
individuals fuly suppressed by cART wil also likely have escape mutations to which the 
CD8+ T cel response of the infected individual may not be able to efectively respond 
(49), further supporting the likelihood that some sort of booster or therapeutic vaccine 
wil likely be necessary for the elimination of the latent reservoir. 
 The folowing studies therefore examine the CD8+ T cel response of HIV-
positive individuals. In the first study, the eficacy of elite suppressor CD4+ and CD8+ T 
cel responses were measured in relation to infected macrophages, the major cel type 
besides CD4+ T cels infected by HIV-1. These cels are thought to be another reservoir 
in patients on cART (50). Both CD4+ And CD8+ T cels were found to be capable of 
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suppressing virus release by infected macrophages, with the CD8+ T cels actively 
causing cel death (51). In the second study, the kinetics of HIV-1 reactivation were 
determined in regards to production of both intracelular HIV-1 mRNA transcript and 
virions, and HIV-specific CD8+ T cels from HIV-positive chronic progressors were 
found to be ineficient at eliminating newly reactivated latently infected CD4+ T cels 
(52). In the third study, the efect of both PKC agonist and HDAC inhibitor latency 
reactivating agents on the CD8+ T cel response was found in many cases to be 
inhibitory, specificaly due to an increase in cel death and CD8+ T cel exhaustion (53). 
Together, these three studies underline the need for both a therapeutic vaccine to be used 
in cure research as wel as careful examination of the efects of latency reactivating 









2. Swanstrom R, Cofin J. 2012. HIV-1 pathogenesis: the virus. Cold Spring Harb 
Perspect Med. 2(12):a007443. doi: 10.1101/cshperspect.a007443. 
 
3. Fraser C, Holingsworth TD, Chapman R, de Wolf F, Hanage WP. 2007. Variation in 
HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. 
Proc Natl Acad Sci U S A. 104(44):17441-6. 
 
4. Centers for Disease Control and Prevention. 1992. 1993 revised classification system 
for HIV infection and expanded surveilance case definition for AIDS among 
adolescents and adults. MMWR Recomm Rep. 41(RR-17):1-19. 
 
5. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F; ATHENA national 
observational cohort study. 2010. Life expectancy of recently diagnosed 
asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 
24(10):1527-35. doi: 10.1097/QAD.0b013e32833a3946. 
 
6. Campbel EM, Hope TJ. 2015. HIV-1 capsid: the multifaceted key player in HIV-1 
infection. Nat Rev Microbiol. 13(8):471-83. doi: 10.1038/nrmicro3503. 
 
7. HIV Sequence Compendium 2015. Brian Foley, Thomas Leitner, Cristian Apetrei, 
Beatrice Hahn, Ilene Mizrachi, James Mulins, Andrew Rambaut, Steven Wolinsky, 
and Bete Korber editors. 2015. Publisher: Los Alamos National Laboratory, 
Theoretical Biology and Biophysics, Los Alamos, New Mexico. LA-UR-15-27742. 
 
8. Chan DC, Fass D, Berger JM, Kim PS. 1997. Core structure of gp41 from the HIV 
envelope glycoprotein. Cel. 89(2):263-73. 
 
9. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional 
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 
272(5263):872-7. 
 
10. Choe H, Farzan M, Sun Y, Sulivan N, Rolins B, Ponath PD, Wu L, Mackay CR, 
LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. 1996. The beta-chemokine 
receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cel. 
85(7):1135-48. 
 
11. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Colman 
RG, Doms RW. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the 




12. Craigie R, Bushman FD. 2012. HIV DNA integration. Cold Spring Harb Perspect 
Med. 2(7):a006890. doi: 10.1101/cshperspect.a006890. 
 
13. Sodroski J, Goh WC, Rosen C, Dayton A, Terwiliger E, Haseltine W. 1986. A 
second post-transcriptional trans-activator gene required for HTLV-II replication. 
Nature. 321(6068):412-7. 
 
14. Malim MH, Hauber J, Le SY, Maizel JV, Culen BR. 1989. The HIV-1 rev trans-
activator acts through a structured target sequence to activate nuclear export of 
unspliced viral mRNA. Nature. 338(6212):254-7. 
 
15. Kim SY, Byrn R, Groopman J, Baltimore D. 1989. Temporal aspects of DNA and 
RNA synthesis during human immunodeficiency virus infection: evidence for 
diferential gene expression. J Virol. 63(9):3708-13. 
 
16. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. 
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 
373: 123–126. 
 
17. Roberts JD, Bebenek K, Kunkel TA. 1988. The accuracy of reverse transcriptase 
from HIV-1. Science. 242(4882):1171-3. 
 
18. Preston BD, Poiesz BJ, Loeb LA. 1988. Fidelity of HIV-1 reverse transcriptase. 
Science. 242(4882):1168-71. 
 
19. Rambaut A, Posada D, Crandal KA, Holmes EC. 2004. The causes and 
consequences of HIV evolution. Nat Rev Genetics. 5: 52-61. doi:10.1038/nrg1246. 
 
20. Gardner MR, Katenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, 
Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES Jr, Felinger CH, Joshi 
VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, 
Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M Jr, Lifson 
JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, 
Farzan M. 2015. AAV-expressed eCD4-Ig provides durable protection from multiple 
SHIV chalenges. Nature. 519(7541):87-91. doi:10.1038/nature14264. 
 
21. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, 
Buckler-White A, Sadjadpour R, Wang K, Mankof Z, Schmidt SD, Lifson JD, 
Mascola JR, Nussenzweig MC, Martin MA. 2016. A single injection of anti-HIV-1 
antibodies protects against repeated SHIV chalenges. Nature. 533(7601):105-9. doi: 
10.1038/nature17677. 
 
22. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, 
Shoemaker R, Li Y, Lewis MS, Giliam AN, Xu G, Whizin N, Burwitz BJ, Planer 
SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Früh K, Sacha JB, Estes JD, 
	  8 
Keele BF, Edlefsen PT, Lifson JD, Picker LJ. 2013. Immune clearance of highly 
pathogenic SIV infection. Nature. 502(7469):100-4. doi: 10.1038/nature12519. 
 
23. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. 1995. Virologic and immunologic 
characterization of long-term survivors of human immunodeficiency virus type 1 
infection. N Engl J Med. 26:201–208. 
 
24. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori 
D, Orenstein JM, Fox C, Schrager LK, Margolick JB, Buchbinder S, Giorgi JV, Fauci 
AS. 1995. Studies in subjects with long-term nonprogressive human 
immunodeficiency virus infection. N Engl J Med. 332:209–216. 
 
25. Ockulicz J, Lambote O. 2011. Epidemiology and clinical characteristics of elite 
controlers. Cur Opin HIV AIDS 6(3):163–168 
 
26. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Halahan CW, 
Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, 
Connors M. 2002. HIV-specific CD8+ T-cel proliferation is coupled to perforin 
expression and is maintained in nonprogressors. Nat. Immuno. 3 (11):1061-8. 
 
27. Bets MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman 
MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV 
nonprogressors preferentialy maintain highly functional HIV-specific CD8+ T-cels. 
Blood 107: 4781-9. 
 
28. Sáez-Cirión A, Lacabaratz C, Lambote O, Versmisse P, Urutia A, Boufassa F, 
Baré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A; Agence Nationale de 
Recherches sur le Sida EP36 HIV Controlers Study Group. 2007. HIV controlers 
exhibit potent CD8 T cel capacity to suppress HIV infection ex vivo and peculiar 
cytotoxic T lymphocyte activation phenotype. PNAS 104 (16): 6776-81. 
 
29. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, 
Berkley AM, Sacha JB, Cogliano-Shuta NA, Lloyd M, Roby G, Kwan R, 
McLaughlin M, Stalings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya 
A, Palmer S, Wiegand AP, Maldareli F, Cofin JM, Melors JW, Halahan CW, 
Folman DA, Connors M. 2008. Lytic granule loading of CD8+ T cels is required for 
HIV-infected cel elimination associated with immune control. Immunity 29:1009–
21. 
 
30. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, 
Rodriguez B, Sieg SF, Teixeira-Johnson L, Gudonis D, Goepfert PA, Lederman MM, 
Frank I, Makedonas G, Kaul R, Walker BD, Bets MR. 2010. Perforin expression 
directly ex vivo by HIV-specific CD8 T-cels is a corelate of HIV elite control. PLoS 
Pathog. 6 (5): e1000917. doi: 10.1371/journal.ppat.1000917. 
 
	  9 
31. Buckheit RW, II, Siliciano RF, Blankson JN. 2013. Primary CD8+ T cels from elite 
suppressors efectively eliminate non-productively HIV-1 infected resting and 
activated CD4+ T cels. Retrovirology 10: 68. doi: 10.1186/1742-4690-10-68. 
 
32. Autran B, Descours B, Avetand-Fenoel V, Rouzioux C. 2011. Elite controlers as a 
model of functional cure. Cur Opin HIV AIDS. 6(3):181-7. doi: 
10.1097/COH.0b013e328345a328. 
 
33. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. 2004. The multifactorial nature 
of HIV-1 latency. Trends Mol Med. 10(11):525-31. 
 
34. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of 
human immunodeficiency virus in T cels. Nature 326: 711–713. 
 
35. Siekevitz M, Josephs SF, Dukovich M, Pefer N, Wong-Staal F, Greene WC. 1987. 
Activation of the HIV-1 LTR by T cel mitogens and the trans-activator protein of 
HTLV-I. Science 238: 1575–1578. 
 
36. Bohnlein E, Lowenthal JW, Siekevitz M, Balard DW, Franza BR, Greene WC. 1988. 
The same inducible nuclear proteins regulates mitogen activation of both the 
interleukin-2 receptor-α gene and type 1 HIV. Cel 53: 827–836. 
 
37. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. 1989. Tumor necrosis factor α 
activates human immunodeficiency virus type 1 through induction of nuclear factor 
binding to the NF-κB sites in the long terminal repeat. Proc Natl Acad Sci 86: 5974–
5978. 
 
38. Finzi D, Hermankova M, Pierson T, Caruth LM, Buck C, Chaisson RE, Quinn TC, 
Chadwick K, Margolick J, Brookmeyer R, Galant J, Markowitz M, Ho DD, Richman 
DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly 
active antiretroviral therapy. Science. 278(5341):1295-300. 
 
39. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, 
Gange SJ, Siliciano RF. 2003. Long-term folow-up studies confirm the stability of 
the latent reservoir for HIV-1 in resting CD4+ T cels. Nat Med. 9(6):727-8.  
 
40. Siliciano JD, Siliciano RF. HIV-1 eradication strategies: design and assessment. 
2013. Cur Opin HIV AIDS. 8:318-25. doi: 10.1097/COH.0b013e328361eaca. 
 
41. Archin NM, Margolis DM. 2014. Emerging strategies to deplete the HIV reservoir. 
Cur Opin Infect Dis. 27:29-35. doi: 10.1097/QCO.0000000000000026. 
 
42. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin 
BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cels. J 
Biol Chem. 2009; 284(11): 6782-9. doi: 10.1074/jbc.M807898200. 
 
	  10 
43. Xing S, Bulen CK, Shrof NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, 
Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF. Disulfiram 
reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cel model without 
inducing global T cel activation. J Virol. 2011; 85(12): 6060-4. doi: 
10.1128/JVI.02033-10. 
 
44. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA. 
Designed, syntheticaly accessible bryostatin analogues potently induce activation of 
latent HIV reservoirs in vitro. Nat Chem. 2012; 4(9): 705-10. doi: 
10.1038/nchem.1395. 
 
45. Bulen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo 
approaches distinguish efective and inefective single agents for reversing HIV-1 
latency in vivo. Nat Med. 2014; 20(4): 425-9. doi: 10.1038/nm.3489. 
 
46. Laird GM, Bulen CK, Rosenbloom DI, Martin AR, Hil AL, Durand CM, Siliciano 
JD, Siliciano RF. 2015. Ex vivo analysis identifies efective HIV-1 latency-reversing 
drug combinations. J Clin Invest. 125(5): 1901-12. doi: 10.1172/JCI80142. 
 
47. Jones RB, O'Connor R, Mueler S, Foley M, Szeto GL, Karel D, Lichterfeld M, 
Kovacs C, Ostrowski MA, Trocha A, Irvine DJ, Walker BD. 2014. Histone 
deacetylase inhibitors impair the elimination of HIV-infected cels by cytotoxic T-
lymphocytes. PLoS Pathog. 10(8):e1004287. doi: 10.1371/journal.ppat.1004287. 
 
48. Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, 
Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, 
Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Østergaard 
L, Tolstrup M. 2015. The Depsipeptide Romidepsin Reverses HIV-1 Latency In 
Vivo. PLoS Pathog. 11(9):e1005142. doi: 10.1371/journal.ppat.1005142. 
 
49. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh 
HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, 
Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavel 
RA, Shan L, Siliciano RF. 2015. Broad CTL response is required to clear latent HIV-
1 due to dominance of escape mutations. Nature. 517(7534): 381-5. doi: 
10.1038/nature14053. 
 
50. Cribbs SK, Lennox J, Caliendo AM, Brown LA, Guidot DM. 2015. Healthy HIV-1-
infected individuals on highly active antiretroviral therapy harbor HIV-1 in their 
alveolar macrophages. AIDS Res Hum Retroviruses. 31(1): 64-70. doi: 
10.1089/AID.2014.0133. 
 
51. Walker-Sperling VE, Buckheit RW 3rd, Blankson JN. (2014) Comparative analysis 
of the capacity of elite suppressor CD4+ and CD8+ T cels to inhibit HIV-1 




52. Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN. (2015) Reactivation 
Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cels 
to HIV-1-Specific CD8+ T Cels. J Virol. 89(18):9631-8. doi: 10.1128/JVI.01454-15. 
 
53. Walker-Sperling VE, Pohlmeyer CW, Blankson JN. (2016) The Efect of Latency 
Reversal Agents on Primary CD8+ T Cels: Implications for Shock and Kil 
Strategies for HIV Eradication. EBioMedicine. doi: 10.1016/j.ebiom.2016.04.019. 
  
	  12 
II. Comparative analysis of the capacity of elite 
suppressor CD4+ and CD8+ T cels to inhibit 
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INTRODUCTION 
 Elite suppressors (ESs) are rare patients who control human immunodeficiency 
virus type 1 (HIV-1) replication without antiretroviral therapy (1). Many studies have 
shown that CD8+ T cels from ESs are more efective at inhibiting viral replication in 
CD4+ T cels than CD8+ T cels from chronic progressors (CPs) (2,–11). Furthermore, 
HIV-1-specific CD4+ T cels from ESs have high-avidity T cel receptors and are more 
likely to maintain responses that are either proliferative, polyfunctional, or cytotoxic than 
effector CD4+ T cels from CPs (12,–19). 
 While HIV-1 also infects macrophages, these target cels are rarely examined in 
the context of immunologic control. Macrophages are thought to be more dificult to 
infect with HIV-1 than activated CD4+ T cels, in part due to diferences in the level of 
expression of retroviral restriction factors, such as tetherin, SAMHD1, and APOBEC3 
(20,–22). SAMHD1 specificaly contributes to the lower concentration of 
deoxynucleoside triphosphates already found in macrophages, greatly inhibiting reverse 
transcription (23, 24). Even though CD4+ T cels are the major reservoir of HIV-1 
infection, the infection of macrophages remains a concern, especialy since these cels 
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can directly infect CD4+ T cels with HIV-1 in an eficient manner (25, 26). Thus, 
examining the celular immune response to HIV-1-infected macrophages wil contribute 
to the rational design of an HIV-1 vaccine. 
 While some CD8+ and CD4+ T cel clones and cel lines have previously been 
shown to suppress HIV-1 or simian immunodeficiency virus (SIV) replication in infected 
macrophages (27,–30), less is known about the inhibitory capacity of unstimulated 
primary T cels. Interestingly, in the macaque model of elite suppression, freshly isolated 
SIV-specific primary CD8+ T cels were able to inhibit viral replication in CD4+ target 
cels but not in macrophages (31). 
 In order to determine whether primary human ES T cels were capable of 
suppressing viral replication in macrophages, we compared the replication kinetics of a 
laboratory HIV-1 isolate in monocyte-derived macrophages (MDMs) in the presence and 
absence of freshly isolated primary CD4+ and CD8+ T cels. Our results provide 
guidance for the development of an efective therapeutic vaccine against HIV-1 infection 





Patients. Al blood was obtained from patients and healthy donors (HDs) after they 
provided writen and informed consent and was handled as recommended by the 
Institutional Review Board of the Johns Hopkins University. The ESs (n = 12) had viral 
loads of less than 50 copies per ml, and the virus in highly active antiretroviral therapy 
(HAART)-treated CPs (n = 11) had been fuly suppressed with antiretroviral therapy for 
at least 1 year. Seronegative controls comprised 20 healthy HIV-1-negative HDs. 
Cel isolation and tissue culture. Peripheral blood mononuclear cels (PBMCs) isolated 
from whole blood via Ficol-Paque Plus gradient centrifugation (GE Healthcare Life 
Sciences) underwent positive selection for CD14+ monocytes using a magneticaly 
activated cel sorting system (CD14 microbeads; Miltenyi Biotec). Monocytes were 
plated at 105 cels per wel in a flat-botomed 96-wel plate with macrophage 
diferentiation medium (RPMI 1600, 20% type human AB serum [U.S. origin; GemCel], 
1% HEPES, 50 ng/ml human recombinant macrophage colony-stimulating factor [R&D 
Systems]) and incubated for 7 days at 37°C (32). PBMCs colected 7 days prior to 
infection were stimulated with phytohemagglutinin in activating medium (100 units 
interleukin-2 [IL-2]/ml) for 3 days before CD4+ T cel targets were isolated by negative 
selection. 
CD4+ and macrophage suppression assay. PBMCs isolated from whole blood via 
Ficol gradient centrifugation on the day of infection underwent positive selection for 
CD8+ T cels (median purity, 94.3%; CD8 microbeads; Miltenyi Biotec) and negative 
selection for CD4+ T cels (median purity, 95.8%; CD4 T cel isolation kit; Miltenyi 
Biotec) to isolate the efector cels used in the suppression assay. MDM and CD4+ T cel 
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targets were spinoculated with HIVBaL(500 ng p24 of virus stock per 10
6 cels was used 
for the standard assay; half that dose was used for MDMs in the experiment for the 
comparison with CD4 targets [32]) for 2 h at 1,200 × g and 37°C (33). Autologous 
CD4+ and/or CD8+ efectors were added to 105 target MDMs or target CD4+ T cels at 
ratios of 1:1, 1:2, and 1:4. CD4+ T cel and MDM targets were cultured in RPMI 1640–
10% fetal bovine serum (FBS). Nonsuperinfected target cels incubated with efector 
cels were used to control for background HIV production. The same number of infected 
target cels used in the experimental conditions was included to determine the maximum 
amount of virus production for calculating percent inhibition, which was calculated as 
100% · [1 – (experimental value/maximum virus production)]. Al efectors remained in 
culture with infected target cels for the entire time span of each experiment. CD4+ T 
cels and MDMs were cultured postinfection with 10 units/ml of IL-2, which was added 
every other day solely for the experiment comparing CD8+ T cel-mediated efector 
inhibition between target cel types. Al other suppression assays were conducted with 
RPMI 1640–10% FBS without IL-2. Culture supernatant was colected for analysis 
immediately after the addition of efectors (day 0) and on days 3, 5, and 7 postinfection. 
Macrophage infection without spinoculation. Monocyte-derived macrophages were 
incubated with HIVBaL (500 ng p24 per 10
6 cels) for 4 h at 37°C. Three-quarters of the 
virus inoculum was removed and replaced with RPMI 1640–10% FBS, and the cels were 
incubated overnight. The remaining virus was then removed and replaced with RPMI 
1640–10% FBS. Culture supernatant was colected immediately after addition of 
efectors (day 0) and on days 3, 5, and 7 postinfection. 
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Transwel macrophage suppression assay. Monocytes isolated 7 days prior to infection 
were plated at 5 × 105 cels per wel on flat-botomed 24-wel plates in macrophage 
diferentiation medium for 7 days at 37°C. After spinoculation with HIVBaL (2 h at 1,200 
× g and 37°C; 500 ng/106 cels), CD4+ and CD8+ efectors were isolated from fresh 
PBMCs and added to the monocyte-derived macrophages at a 1:1 ratio either directly or 
in a transwel (Corning transwel permeable supports). Supernatant was colected 
immediately after addition of efectors (day 0) and on days 3 to 7 postinfection. 
Viral output and efector cel infection. Viral production in the culture supernatants 
was determined via p24 enzyme-linked immunosorbent assay (ELISA; PerkinElmer) per 
the manufacturer's instructions. For fluorescence-activated cel sorting, T cel efectors 
were stained with the extracelular markers CD3-Pacific Blue and CD8-alophycocyanin-
H7 (BD Biosciences). Cels were permeabilized with Cytofix/Cytoperm (BD 
Biosciences) and then stained with Coulter clone K57-RD1 (HIV-1 core antigen, FL-2 
channel). Fluorescence data were colected on a BD FACSCanto I flow cytometer and 
analyzed with FlowJo software. 
Cytotoxicity assay. Macrophages were diferentiated and infected with HIVBaL as 
described above for the suppression assay. PBMCs were acquired on the day of 
macrophage infection and stimulated with Gag peptides (10 µg/ml) and 10 units/ml of IL-
2 for 1 week. After 7 days of culture after HIVBaL infection, the macrophage culture 
medium was changed. Stimulated and unstimulated primary CD4 and CD8 efector cels 
were added at a 1:1 efector cel/target cel ratio. Supernatant was harvested from the 
cultures at 24 h after addition of the efectors and analyzed for lactate dehydrogenase 
(LDH) release using a Cytotox-96 nonradioactive cytotoxicity assay (Promega) per the 
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manufacturer's instructions (34). Infected macrophages without any efectors were used 
as a spontaneous target cel death control, and efectors cultured alone were used as a 
spontaneous efector cel death control. Maximum LDH release was determined by 
treating macrophages with 0.5% Triton-X for maximum cel death. Percent cytotoxicity 
was calculated as folows: 100% · (experimental LDH release – spontaneous target cel 
LDH release – spontaneous efector cel LDH release)/(maximum LDH release – 
spontaneous target cel LDH release). 
Statistical analysis. Statistical analyses were performed using GraphPad Prism (version 
6) and Microsoft Excel software. Unpaired, two-tailed Student's t tests were used for 
comparing ES and HAART efector responses in the macrophage suppression and 
cytotoxicity assays. A paired, two-tailed Student's t test was used to examine directly 





 In order to examine the T cel response to macrophage infection in HIV-positive 
individuals, we first examined the susceptibility of monocyte-derived macrophages 
(MDMs) from 12 ESs, 11 CPs on suppressive HAART regimens, and 19 HDs to HIV-1 
infection. Using spinoculation and a replication-competent virus (HIVBaL), we found that 
there was no diference in the amount of virus produced by MDMs from ESs, CPs, and 
HDs by day 7 postinfection (Fig. 1A and B). To determine whether there were subtle 
diferences in the susceptibility to infection that were masked by spinoculation, we 
performed the infectivity assay without spinoculation in macrophages from randomly 
selected subsets of ESs and HDs (n = 4 for each; Fig. 1C). We found that, under these 
conditions, HIVBaL was similarly capable of infecting MDMs from both ESs and HDs. 
Taken together, these data suggest that there is no significant diference in the 
susceptibility of MDMs from ESs, CPs, and HDs to HIV-1 infection. 
 Strong CD8+ T cel responses to HIV-1-infected CD4+ T cels have been 
documented in many ESs; thus, we examined the ability of unstimulated primary ES 
CD8+ T cels to suppress viral replication in MDMs using a variation of a previously 
described inhibition assay (4, 35). The responses elicited by the CD8+ efectors were 
divided into three categories on the basis of the distribution of the degree of inhibition 
observed in al the patients studied. T cels from some patients mediated either (i) a low 
degree of inhibition (defined as less than 35% inhibition), (i) an intermediate degree of 
inhibition (defined as between 35 and 65% inhibition), or (ii) a high degree of inhibition 
(defined as greater than 65% inhibition). The ES CD8+ T cels mediated a high degree of 
inhibition on days 5 and 7. CD8+ T cels from CPs 1 to 4 (Table 1) were also found to 
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mediate high levels of inhibition, but the ES CD8+ T cel response was found to be 
significantly superior on day 7 (P < 0.02; Fig. 2A). While coincubation of infected 
macrophages with CD8+ T cels from ESs resulted in high levels of inhibition in al 
patients except ES5, the responses seen in CPs were much more heterogeneous, with the 
majority of patients having intermediate or low levels of inhibition (Fig. 2B). Low-level 
to no inhibition was seen in 16 out of 18 HDs at day 5 and 18 out of 18 HDs at day 7. 
Interestingly, when the CD8+ efector response to MDM targets was compared to the 
response to CD4+ T cel targets in ESs, a similar level of inhibition was observed on days 
5 and 7 (Fig. 2C). The method by which CD8+ T cels were isolated did not seem to 
change the suppressive ability, as purification of the cels by positive selection and 
negative selection resulted in similar levels of inhibition (Fig. 2D). Taken together, our 
data demonstrate that ES CD8+ T cels efectively inhibit viral replication in MDMs, and 
this inhibition appears to be a corelate of protective immunity. 
 Although CD4+ T cels are typicaly viewed as the targets of HIV infection, these 
cels can also act as efector cels and have been shown to be capable of suppressing 
infection in macrophages in the macaque model of elite suppression (30). Thus, we 
examined whether or not human ES CD4+ T cels could mediate inhibition of viral 
replication in macrophages. On day 5 after infection, high levels of inhibition were seen 
in ESs 4, 6, 8, 9, and 31 as wel as CPs 2, 5, 7, and 9, while an intermediate level of 
inhibition was seen in ESs 22 to 24 and CPs 1, 4, 6, and 8, making the distribution 
virtualy identical (P = 0.95). At day 7, high levels of inhibition were seen in ESs 4, 6, 8, 
and 31 as wel as CPs 1, 2, 5, 7, and 9 (Fig. 3A). The distribution of the degree of 
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inhibition was nearly identical in ESs and CPs on day 7, and high levels of inhibition 
were not seen in any HD (Fig. 3B). 
 We next compared the magnitude of the CD4+ and CD8+ T cel-mediated efector 
responses to target MDMs. The CD8+ T cel-mediated inhibitory responses in ESs were 
significantly stronger than the CD4+ T cel-mediated inhibitory responses (P < 0.007; Fig. 
4). In contrast, no significant diference in the inhibitory responses mediated by 
CD4+ and CD8+ T cels was seen in CPs or HDs. 
 In order to clarify the mechanisms of inhibition mediated by the two diferent 
efector cels, we performed a variation of the inhibition assay where we used the 
transwel system to separate efector cels from infected target cels. In ESs, some 
inhibition of viral replication was stil seen when efector CD4+ T cels were not in direct 
contact with MDMs (Fig. 5A and B), suggesting that soluble factors were contributing to 
the control of viral replication. In contrast, no inhibition was seen when ES CD8+ T cel 
efectors were physicaly separated from the infected target cels, suggesting that direct 
cel-to-cel contact was critical for the control of viral replication (Fig. 5C and D; P = 
0.015). Similar results were obtained for CPs (data not shown). 
 Using a cytotoxicity assay, we sought to verify that the CD8+ response against 
infected macrophages was indeed a result of cytolytic CD8+ T cels. While there was a 
modest response in ES6 for unstimulated CD4+ efectors as wel as CD4+ and CD8+ T 
cel efectors that had been stimulated for 7 days with overlapping Gag peptides, the only 
strong cytotoxic responses were seen with Gag peptide-stimulated CD8+ efectors for 
both ESs (n = 6) and CPs (n = 5) at 24 h after efector addition (Fig. 6A). The transwel 
system was again used to determine if this response was dependent upon cel-cel contact, 
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and we found that Gag peptide-stimulated CD8+T cel efectors were incapable of kiling 
infected macrophages when they were separated by transwels (Fig. 6B). For ES6, we 
also demonstrated that antibodies to class I blocked the CD8+T cel-mediated kiling (data 
not shown). Together, our results suggest that the vast majority of CD4+ T cel efectors 
in the ESs and CPs that we studied were not able to kil infected macrophages after 24 h 
of coculture even when those cels were prestimulated with Gag peptides (Fig. 6B). 
 Because efector CD4+ T cels are susceptible to infection, we hypothesized that 
they were infected with HIV-1 during the course of experimentation. Therefore, we 
determined what percentage of efector cels were infected by staining for intracelular 
Gag using flow cytometric analysis. On day 7 after infection, the CD4+ T cel efectors 
from ESs, CPs, and HDs were found to be infected to similar degrees, with no significant 
diference seen at three diferent efector cel-to-target cel ratios (Fig. 7A). Furthermore, 
in ESs, a high level of infection of CD4+ T cel efectors occured by day 3 postinfection 
(Fig. 7B), which could potentialy explain the lower level of inhibition seen at later time 
points in some patients (Fig. 3A). Infection of efector CD4+T cels did not corelate with 
their ability to inhibit viral replication in macrophages in our combined cohort of ESs and 
CPs (Fig. 7C). While this lack of corelation held true for ESs when they were examined 
separately (Fig. 7D), there was a significant corelation between the degree of viral 
inhibition and the percentage of infected CD4+ T cel efectors in CPs (R2 = 0.82, P = 





 Many lines of evidence suggest that the cause of elite suppression in some 
patients is a result of an eficient CD8+ T cel response that prevents ongoing viral 
replication. This idea has long been supported by both functional studies examining the 
response and quality of ES CD8+ T cels (2, 3, 5, 10, 36-40) and genome-wide 
association studies identifying major histocompatibility complex class I aleles (such as 
HLA-B*57 and HLA-B*27) (41-46). In addition, these protective HLA aleles have been 
shown to be overepresented in multiple ES cohorts (4, 41, 47-52). While many studies 
have focused on the control of viral replication in CD4+ T cels, a few studies have 
looked at the ability of human T cel clones to kil macrophages. As with CD8+cytotoxic 
T cel clones and monocyte and dendritic cel targets (53), Nef-specific cytotoxic CD4+T 
cels were found to be capable of eficiently kiling both CD4+ T cel and macrophage 
targets (28, 29). Similarly, in the macaque model of elite suppression, CD4+ T cel clones 
were capable of suppressing the infection of macrophages (30). Given the importance of 
macrophages in the pathology of HIV infection (54), determining whether or not efector 
T cels can control viral replication in these cels is essential for the rational design of a 
vaccine. In this study, we demonstrate that unstimulated, primary CD8+ T cel efectors 
from ESs are capable of efectively suppressing viral replication in macrophages. 
 Despite previous evidence to the contrary (55), macrophages from ESs seem to be 
able to be infected to the same degree as macrophages from patients on HAART and 
healthy donors. Similar results were obtained with and without spinoculation using the 
same replication-competent virus that was used in the prior study. While residual 
intracelular antiretroviral drugs may have resulted in low-level inhibition of HIV-1 
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replication in CP MDMs, this would not explain the lack of a significant diference in the 
replication kinetics between ES and HD MDMs. Macrophages in diferent activation 
states have been known to be diferentialy susceptible to infection (56, 57), so the 
disparity between our results and previous findings may be a result of the methods used 
to induce the diferentiation of monocytes into macrophages. 
 In contrast to the macaque model of elite suppression, where SIV-specific CD8+ T 
cel efectors were inefective at inhibiting viral replication in macrophages (31), we 
show here that primary CD8+ T cels from ESs eficiently inhibited virus production in 
MDMs. This suppression was cel contact mediated and probably the result of cytotoxic 
responses, as previously described (2, 5, 10, 58). The CD8+ efector inhibitory response 
to HIV-1-infected macrophages was significantly more potent in ESs than HAART 
patients. However, a few individuals on HAART had primary, inhibitory CD8+ T cel 
responses that were comparable to the responses seen in ESs. In contrast, there was a 
marked diference in the kiling of infected macrophages between Gag peptide-stimulated 
CD8+ T cels from ESs and stimulated CD8+ T cels from patients on HAART. This 
diference is similar to the diferences in the capacity of CD8+ T cels from ESs versus 
those from CPs to eliminate HIV-infected CD4+ T cels seen previously (5). Interestingly, 
CD8+ T cels from some healthy donors induced a low level of inhibition of viral 
replication in autologous macrophages. This is contrast to the findings of our prior 
studies, where we saw no inhibition of viral replication in CD4+ T cels by CD8+ T cels 
from healthy donors (11, 35, 59). It is possible that this inhibition may represent an innate 
immune response or the development of an adaptive response during the 7-day period of 
coculture of infected macrophages and CD8+ T cels. Taken together, while ESs clearly 
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have a superior inhibitory CD8+ T cel response against HIV-1-infected macrophages, on 
average, it is possible that this phenotype alone is not suficient to explain elite control in 
al patients. 
 In contrast to the responses seen with CD8+ T cel efectors, there was no 
significant diference in the ability of primary CD4+ T cel efectors from ESs and CPs to 
inhibit viral replication in macrophages. Within the ES group, the CD4+ inhibitory 
response was also consistently inferior to the response mediated by CD8+ efectors. 
Interestingly, some ESs and CPs had strong CD4+ T cel inhibitory responses. This 
inhibition appeared to be mediated by both soluble factors and a cel contact-dependent 
mechanism. Potential soluble factors involved in the response include RANTES and 
macrophage inflammatory protein-1-alpha/beta, which inhibit the entry of CCR5-tropic 
viruses and have been associated with HIV-specific CD4+ T cel responses (12, 60). With 
regard to the cel contact-mediated suppression, prior studies have shown that some 
CD4+efectors may have cytotoxic activity against HIV-1-infected CD4+ T cels 
(15, 27, 29, 30, 61–64). However, we saw very litle CD4+-mediated kiling of infected 
macrophages over a 24-h period in this study. It is possible that CD4+ T cels are capable 
of kiling over a longer time frame, but, in general, the CD4+ T cel efector response to 
macrophages does not appear to be a corelate of immunity in our cohort of patients. 
 Eight out of nine of the ESs studied here have the protective HLA B*27 and/or 
B*57 class I aleles (Table 1). In contrast, some ESs in other larger cohorts do not have 
these protective aleles or strong HIV-specific CD8+ T cel responses (8, 49, 51, 65). It 
would be interesting to determine whether suppressive CD4+ responses play a role in the 
control of viral replication in these patients. With that said, we show here that 
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CD4+ efector cels are susceptible to infection, and this may limit the efectiveness of 
CD4+ cytotoxic T cels. We observed a negative corelation between the susceptibility to 
infection and the suppressive capacity of efector CD4+ T cels in CPs, and the decline in 
Gag-positive CD4+ efector T cels over time could be due to the cytopathic efects of the 
virus. These data suggest that efector CD4+ T cels could potentialy have significant 
antiviral activity if they were engineered to be resistant to HIV-1 infection (66). 
 Our data are limited by the relatively low number of patients studied and the fact 
that we did not include viremic CPs in our analysis. The numbers of efector CD8+ T 
cels decline over time in patients on HAART (67), so it possible that the lower level of 
CD8+ T cel-mediated inhibition in CPs was due to the lower number of efector CD8+ T 
cels in these patients. We tried to address this issue by stimulating CD8+ T cels with 
Gag peptide prior to doing a cytotoxic T lymphocyte assay, but we stil saw a marked 
diference in the kiling of infected cels by efector cels in ESs and CPs. The results are 
consistent with those of a prior study that showed that ES CD8+ T cels are more efective 
than CP CD8+ T cels at kiling infected CD4+ T cels on a cel-per-cel basis (5). 
In conclusion, primary, unstimulated CD8+ T cels from ESs are capable of suppressing 
the macrophage production of replication-competent HIV-1 in a cel contact-mediated 
manner that is superior to the suppression mediated by CD8+ T cels in patients on 
HAART. Macrophages are resistant to viral cytopathic efects and are the primary target 
cel in the central nervous system (53, 68). Thus, the induction of CD8+ T cels that 
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III. Reactivation Kinetics of HIV-1 and 
Susceptibility of Reactivated Latently Infected 
CD4+ T Cels to HIV-1-Specific CD8+ T Cels 
 
 
This chapter has previously been published in the Journal of Virology: 
 
Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN. (2015) Reactivation 
Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cels to 




  The goal of “shock and kil” HIV cure strategy is to selectively reactivate 
latent HIV-1 transcription without causing global T cel activation in order for the 
immune system to be able to recognize and eliminate latently infected cels (reviewed in 
1 and 2). The presence of antiretroviral drugs during treatment with latency reversal 
agents wil prevent reactivated virus from infecting other CD4+ T cels even if the kil 
component of the shock and kil strategy is not efective. However, subjects wil 
eventualy cease ART after treatment is deemed to be successful. As several recent cases 
have shown, residual latently infected cels may lead to a rebound in viremia and the re-
establishment of a chronic HIV-1 infection (3-5) even when frequency of infected cels 
is lower than 1 in 150 milion peripheral CD4+ T cels (3). Therefore, the ability of CD8+ 
T cels to kil newly-reactivated, latently-infected cels before the completion of the viral 
life cycle may be very important. 
 Through viral dynamics modeling combined with viral load data, the lifetime of 
an infected cel has been estimated using viral load data to be around 2 days from 
atachment of the virion to the death of the cel (6-9). Reactivated latently infected cels, 
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on the other hand, re-initiate the viral life cycle from proviral transcription onwards 
cuting down the time from activation to virus release. When activation of latently 
infected CD4+ T cels occurs, there is translocation of transcription factors such as NFkB 
and NFAT that alow for reactivation of the HIV-1 provirus (10-13). HIV-1 infected 
CD4+ T cels first produce the early proteins, Tat, Rev, and Nef, from a fuly spliced HIV 
transcript (14-15). The production of Nef may complicate the ability of the CD8+ T cel 
response to eliminate infected cels by downregulating HLA-A and -B proteins (16-19). 
The timing and magnitude of this downregulation may adversely afect the ability of 
CD8+ T cels to adequately eliminate the latently infected CD4+ T cels. 
 To model the events needed for the rapid elimination of reactivated latently 
infected CD4+ T cels, we monitored the kinetics of transcription and virion release after 
the stimulation of primary CD4+ T cels from subjects on suppressive CART regimens. 
We used a primary CD4+ T cel model that involved nucleofection of cels with HIV-1 
plasmids to determine the kinetics of protein production folowing proviral transcription 
in addition to HLA downregulation folowing viral protein expression. We then 
determined whether or not stimulated HIV-specific CD8+ T cels could eliminate 
infected autologous CD4+ cels before completion of the viral life cycle. Our results 
suggest that a successful therapeutic vaccine may need to induce efector CD8+ T cels 




HIV+ and HIV- Donor Blood Samples. Al blood was obtained from HIV+ subjects 
and HIV- donors with writen and informed consent and handled as per Johns Hopkins 
University regulations. The chronic progressors were HIV-1 infected subjects who were 
started on suppressive ART regimens during chronic infection and had maintained viral 
loads of < 50 copies HIV-1 RNA/ml with no blips for a median of 4 years (range of 1 to 
13 years). The viremic controlers maintained a median viral load of 295 copies/ml (range 
of 80 to 1133 copies/mL) without cART (Table). 
Primary Resting Cel Isolation. PBMCs isolated from whole blood via Ficol-Paque 
PLUS gradient centrifugation (GE Healthcare Life Sciences) underwent negative 
selection for CD4+ T cels using the MACS system (CD4 Isolation Kit, Miltenyi Biotec). 
The CD4+ T cels were further depleted CD25-, CD69-, and HLA-DR-expressing cels 
with Miltenyi microbeads (CD25 microbeads, CD69 Isolation Kit, and HLA-DR 
microbeads) for the isolation of the resting cels. 
Outgrowth of Latent HIV-1. Resting CD4+ T cels were plated at a concentration of 
5x106 cels per mL with up to 3 replicates of each experimental condition in 12-wel 
plates and incubated overnight in non-activating media (RPMI 1640, 10% FBS) prior to 
the time-zero supernatant sample. For the general time course (supernatant samples taken 
at 0, 6, and 24 hours and cels at 24 hours), 5x106 resting CD4+ T cels were plated for 
each replicate. After the time-zero supernatant sample, al the cels save for the non-
stimulated control wels were treated for 6 hours with PMA (50 ng/mL) and ionomycin (1 
µM) in the presence of raltegravir (4 µM, RAL) and efavirenz (10 µM, EFV) to prevent 
new infection. For the longer time course, a supernatant sample was taken at the 
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conclusion of the 6 hours, and the resting CD4+ T cels were washed twice prior to re-
plating at 5x106 cels per 2 mL in fresh 12-wel plates with raltegravir (4 µM, RAL) and 
efavirenz (10 µM, EFV) to prevent new infection. Subsequent supernatant samples were 
taken 24 hours. For each replicate at 24 hours, 100-500x103 cels were removed for 
FACS analysis of activation, and the remaining 4.5-4.9x106 CD4+ T Cels were placed 
into TRIzol (Life Technologies) for the isolation of intracelular viral RNA. For the time 
course examining upregulation of intracelular HIV-1 mRNA very early after stimulation 
(0, 1, 3, and 6 hours), 7.5x106 resting CD4+ T cels were plated for each replicate and 
treated with PMA and ionomycin in the presence of raltegravir and efavirenz as above. 
At each time point, 7.4x106 cels were harvested from each replicate and placed in TRIzol 
with 100x103 cels were removed for FACS analysis of activation. Supernatant samples 
were likewise taken from the coresponding wel for RNA isolation.  
Intracelular and Supernatant RNA isolation. Intracelular RNAs were isolated via 
TRIzol (Life Technologies) at a ratio of 5-7.5x106 CD4+ T cels per 1 mL of reagent and 
incubated on a Phase Lock Gel Heavy spin column (5Prime) for five minutes with 
GlycoBlue Coprecipitant (Life Technologies) per manufacturer’s instructions to beter 
facilitate RNA recovery. Chloroform was subsequently added to TRIzol at a 1:5 ratio and 
shaken wel for at least 15 seconds to mix before centrifugation at 12,000 xg for 10 
minutes at 4°C. The top layer of supernatant from the gel tube was transfered to a new 
tube with isopropanol at a 1:2 ratio and incubated for 10 minutes at room temperature to 
precipitate the RNA. The newly precipitated RNA was centrifugated at 12,000 xg for 10 
minutes at 4°C, and the resulting pelet washed with 80% EtOH. After another 
centrifugation with the same setings, the RNA pelet was resuspended in molecular 
	  39 
biology-grade distiled water. Viral RNA was isolated from 250 µL supernatant samples 
with 750 µL TRIzol LS (Life Technologies) and the above protocol. 
Viral Quantification Assay. Viral RNA was quantified as described previously (20,21), 
the process of which is summarized as folows. Isolated intracelular and extracelular 
RNA were converted to cDNA with qScript cDNA SuperMix (Quanta Biosciences) per 
manufacturer’s instructions (5’ at 25°C, 30’ at 42°C, 5’ at 85°C, hold at 4°C). The cDNA 
was then used in a viral quantification assay, a highly sensitive real-time PCR assay that 
specificaly measures HIV-1 mRNA transcripts previously described (20). Supernatant 
RNA samples were measured on a Roche LightCycler 480 Real-Time PCR thermocycler 
with TaqMan Fast Advanced Mastermix (Applied Biosystems) run as per manufacturer’s 
instructions and the folowing primers: Forward (5′→3′) 
CAGATGCTGCATATAAGCAGCTG (9501–9523), Reverse (5′→3′) 
TTTTTTTTTTTTTTTTTTTTTTTTGAAGCAC (9629-poly A). The probe used is as 
folows: (5′→3′) FAM-CCTGTACTGGGTCTCTCTGG-MGB (9531–9550) (al 
nucleotide coordinates relative to HXB2 consensus sequence). Molecular standard curves 
were generated using serial dilutions of a TOPO plasmid containing the final 352 
nucleotides of viral genomic RNA with 30 deoxyadenosines appended to the end. 
CD8+ T Cel Suppression Assay. PBMCs isolated from whole blood via Ficol-Paque 
PLUS gradient centrifugation (GE Healthcare Life Sciences) were stimulated with 
overlapping consensus Gag peptides (10 µg/mL) and IL-2 (10 units/mL) for 7 days. 
CD8+ T cels were isolated from the stimulated PBMCs by positive selection (CD8 
Microbeads, Miltenyi Biotec; purity routinely greater than 95%) concurently with the 
isolation of resting CD4+ T cels from whole blood described above (“Outgrowth of 
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Latent HIV-1”). The CD8+ cels were then cultured in RPMI 1640 with 10% FBS until 
the conclusion of the 6-hour stimulation of the CD4+ T cels with PMA and ionomycin. 
The CD8+ T cels were added in a 1:1 efector:target ratio to the CD4+ T cels after 
washing of the PMA and ionomycin from culture and incubated with entry inhibitors 
EFV and RAL. Subsequent supernatant samples were taken 24 hours. Viral release and 
production of intracelular viral RNA were determined in the same manner as described 
above. 
FACS Analysis. Primary CD4+ T cels examined for production of latent virus were 
stained with CD3-PacBlue, CD4-phycoerythrin (PE), CD8-alophycocyanin (APC)-H7, 
CD25-fluorescein isothiocyanate (FITC), CD69-BV605, and HLA-DR–peridinin 
chlorophyl protein (PerCP)–Cy5.5 (BD Biosciences) to confirm the endpoint activation 
state. 
Statistical Methods. Statistical analyses performed were conducted using Wilcoxon 
matched-pairs signed rank test, the nonparametric alternative to the paired t-test. The 
nonparametric tests were used since many of the measurements evaluated were skewed 
and failed to meet the assumptions required for parametric tests. In addition, the matched-





Kinetics of Virion Release from Latently Infected CD4+ T Cels 
 Resting CD4+ T cels from ART-treated chronic progressors (CPs) were 
stimulated with PMA and ionomycin for 6 hours to induce reactivation of latent HIV and 
virion production. Stimulation was performed in the presence of the non-nucleoside 
reverse transcriptase inhibitor efavirenz (EFV) and the integrase inhibitor raltegravir 
(RAL), to prevent new infection events. HIV-1 mRNA was detected in 9 of 12 CPs 
examined. In 7 of these subjects, HIV-1 mRNA was detected in the culture supernatant 
as early as 6 hours after initiation of PMA and ionomycin treatment (Figure 1). The level 
of HIV-1 RNA detected in the supernatant from 0-6 hours and from 6-24 hours was 
significantly higher than the baseline level (p = 0.01 and p = 0.011, respectively); 
however, there was no statistical significance between the amount of mRNA detected in 
the supernatant at the 2 later time points (Figure 1). 
 Due to the detection of HIV-1 mRNA in culture supernatant as early as 6 hours, 
earlier time points were interogated for upregulation of viral transcription and virion 
release in 8 CPs. Intracelular HIV-1 mRNA was significantly upregulated from baseline 
after 1 hour of PMA and ionomycin treatment (p = 0.017) and remained high through at 
least the next 5 hours (Figure 2). This upregulation has an average 4.96±1.42 fold 
increase from baseline to 1 hour of stimulation and an average 4.74±1.28 fold increase 
from baseline to 6 hours of stimulation. However, there was no significant increase in the 
level of mRNA at later time points compared to 1 hour post-stimulation. Low level HIV-
1 mRNA was present in the supernatant (591-1863 copies) as early as 6 hours post 
initiation of PMA and ionomycin treatment in 3 of the these 5 CPs. Interestingly, very 
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low levels of HIV-1 mRNA (524 copies) was seen in culture supernatant at 3 hours after 
stimulation of CP10 CD4+ T cels (data not shown).  
CD8+ T Cel-Mediated Elimination of Latently-Infected CD4+ T Cels 
 CD8+ T cels stimulated for 7 days with overlapping Gag peptides were co-
cultured for 18 hours with resting patient CD4+ T cels pre-treated with PMA and 
ionomycin for 6 hours in the presence of RAL and EFV. Intracelular HIV mRNA was 
also quantified from non-stimulated resting CD4+ T cels and PMA and ionomycin-
treated CD4+ T cels in the presence of RAL and EFV. Of the 7 CP examined, only 
CD8+ T cels from CP13 were capable of reducing the amount of intracelular HIV-1 
mRNA by a log (14.4 fold decrease from stimulation alone; Figure 3a). However, modest 
elimination of CD4+ T cels expressing intracelular mRNA was also seen folowing co-
culture with CD8+ T cels from CP16 (3.72 fold decrease) and CP18 (3.80 fold decrease). 
Overal, however, there was no significant diference in the amount of HIV-1 mRNA 
found in the stimulated CD4+ T cels versus the stimulated CD4+ T cels co-cultured 
with CD8+ efectors in chronic progressors (p = 0.114; Figure 3b). 
 Elite controlers or suppressors (ES) have more efective HIV-specific CD8+ T 
cel responses than CPs (24-29) however these subjects have very low frequencies of 
latently infected CD4+ T cels (30) and low levels of inducible cel associated HIV-1 
mRNA (31). Therefore, we analyzed viremic controlers (VCs) as these subjects 
maintain low level viremia but have higher frequencies of latently infected cels than ES 
(32) and HIV-specific CD8+ T cel responses that are similar to the responses seen in ES 
(33). These subjects were chosen to further examine whether a cytotoxic T lymphocyte 
response would be capable of eliminating CD4+ T cels that had upregulated intracelular 
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HIV-1 mRNA ex vivo. As with the CPs, culture supernatant from stimulated CD4+ T 
cels isolated from VCs had detectable HIV-1 mRNA as early as 6 hours post initiation of 
PMA and ionomycin treatment (1497-13,883 copies/mL, data not shown). The presence 
of RAL and EFV in the culture medium ensures that only viral DNA that was integrated 
into the host genome was amplified. Co-culture of CD4+ T cels with autologous CD8+ T 
cels from subjects VC1 and VC12 resulted in levels of intracelular mRNA that were 
lower than the baseline seen in unstimulated CD4+ T cels (>10-fold reduction, Figure 4). 
However when al 4 VCs were analyzed together, CD8+ T cels did not have a significant 




 HIV-1 cure strategies are curently focused on a way to eliminate the latent 
reservoir. The end goal of any of these cure strategies is to eventualy take subjects of 
cART. During the curative strategies, the presence of cART wil prevent CD4+ T cels 
from becoming infected by residual virus. However, if any reservoirs of HIV-1 persist 
when cART is discontinued, a rebound in viremia is likely to eventualy occur (3–5). For 
this reason, a CD8+ T cel response capable of control must be developed in order to 
prevent residual latently infected CD4+ T cels from reestablishing chronic infection. In 
this study, we sought to determine the kinetics of reactivation in latently infected cels in 
order to define the time frame in which an efective HIV-specific CD8+ T cel must 
respond. 
 A single CD4+ T cel is thought to produce enough virus to productively infect 
another 3 to 34 new cels per viral generation (34, 35). An efective way of preventing a 
rebound in viremia folowing a curative procedure would be to develop CD8+ efectors 
that target infected cels before they are able to release enough virions to infect other 
CD4+ T cels. Our studies suggest that virus is released from reactivated latently infected 
cels as soon as 6 h after stimulation (Fig. 1). In contrast, intracelular mRNA is 
upregulated as soon as 1 h after stimulation (Fig. 2). While this very quick time frame 
difers from the previous reports of a 2-day viral generation time (6–9), our study directly 
examines HIV-1 mRNA that is produced from reactivated latently infected cels and 
therefore does not include the viral entry, reverse transcription, and integration steps. 
Based on our findings, CD8+ T cels would have at most a 6-h window to efectively kil 
reactivated latently infected CD4+ T cels before viral spread occured. 
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 Coincubation of stimulated CD4+ T cels with autologous CD8+ T cels resulted in 
greater than 1-log-unit reduction in intracelular HIV-RNA in two of four viremic 
controlers and one of seven CPs on cART (Fig. 3A and 4). The low frequency of 
efective kiling by CP CD8+ T cels seen here may be partialy due to the fact that the 
frequency of HIV-specific CD8+ T cels decreases in subjects on cART (36), and 7 days 
of stimulation with HIV-1 peptides may not have resulted in adequate expansion of these 
cels (24, 37). The suboptimal T cel response is also in contrast to other recently 
published studies that looked at stimulated primary CD8+ T cels or CD8+ T cel lines 
(38, 39). The diferences may be partialy due to the fact that some experiments from the 
other studies used superinfection of CD4+ T cels with autologous virus and measured a 
decrease in p24 production over several cycles of viral replication, whereas we looked at 
upregulation of endogenous viral mRNA over a 24-h period folowing stimulation in the 
presence of antiretroviral drugs. In one study, CD8+ T cels were able to suppress virus 
release from the latent reservoir after treatment of CD4+ T cels with latency reversal 
agents (39). Diferences in CD8+T cel stimulation and expansion and the fact that our 
study measured intracelular mRNA, whereas the other study measured extracelular 
RNA may partialy explain the discordant results in the two models. 
 Our results may be limited by the fact that the PMA and ionomycin treatment we 
used to stimulate CD4+ T cels may lead to kinetics of reactivation that are diferent from 
those seen in vivo for CD4+ T cels, which become activated when their T cel receptors 
(TCRs) bind to their cognate antigen and receive a second activating signal from an 
antigen-presenting cel. However, the low frequency of latently infected CD4+ T cels 
that recognize any given antigen necessitates the use of polyclonal T cel stimulation. It is 
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also possible that PMA and ionomycin may have had an efect on the CD8+ T cel 
response as has been shown for the latency reversal drug vorinostat in in vitro studies 
(40), but not in ex vivo studies (39). While we removed culture supernatant containing the 
drugs before adding CD8+ T cels, we cannot rule out the possibility that residual drugs 
may have had an efect on the efector T cel response. The measurement of mRNA 
rather than viral proteins may have also confounded our results, since some cels that 
express viral RNAs may not necessarily make proteins to be recognized by CD8+ T cels 
(41). In spite of these limitations, our study represents a model that may approximate 
what occurs when a latently infected CD4+ T cel becomes reactivated. 
 In summary, we designed experiments to determine the parameters necessary for 
an efective HIV-specific CD8+ T cel response to reactivated latently infected CD4+ T 
cels. We examined the reactivation kinetics after CD4+ T cel stimulation with resting 
CD4+ T cels from chronic progressors and viremic controlers and defined a 5-h window 
between transcription and the release of extracelular viral mRNA. This short time frame 
may represent a significant chalenge for the adaptive immune response, since it wil take 
time for naive and central memory CD8+ T cels to diferentiate into efector cels that are 
capable of inhibiting HIV-1 replication (42). In contrast, efector memory CD8+ T cels 
are more efective at inhibiting viral replication at early time points (42), and a 
cytomegalovirus (CMV)-based vaccine that induced simian immunodeficiency virus 
(SIV)-specific effector memory CD8+ T cels was efective at clearing latently infected 
cels in SIV-infected monkeys (43). Furthermore, studies have shown that stimulated 
CD8+ T cels from some elite suppressors can kil productively infected CD4+ T cels 
within an hour (27), and we demonstrate here that stimulated CD8+ T cels from two of 
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four VCs and one CP are capable of eliminating CD4+ T cels that upregulate HIV-1 
mRNA folowing reactivation. Our data serve as an important proof-of-concept study that 
suggests that with efective therapeutic immunization, CD8+ T cels from CPs may be 
capable of efectively kiling reactivated latently infected CD4+ T cels that may stil 
persist folowing curative strategies. These CD8+ T cels would thus be capable of 
preventing viral rebounds and the reestablishment of a chronic infection if curative 
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IV. The Effect of Latency Reversal Agents on 
Primary CD8+ T Cels: Implications for Shock 
and Kil Strategies for HIV Eradication 
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 Latently infected CD4+ T cels are the major barier to HIV-1 cure eforts. The 
cels contain integrated proviruses that are transcriptionaly silent and thus able to evade 
detection and clearance by the immune system. The shock-and-kil cure strategy seeks to 
first reactivate these latent viruses without causing global T cel activation folowed by 
clearance of the reactivated cels by the immune system (reviewed in 1 and 2). Latency 
reactivating agents (LRAs) are drugs that induce HIV-1 transcription. Notable drug 
classes include PKC agonists and HDAC inhibitors (HDACi), which have been very 
efective in inducing HIV-1 transcription in cel lines (3-6). Unfortunately, in vitro 
experiments with primary resting CD4 T cels from patients on suppressive antiretroviral 
therapy (ART) regimens suggest that most individual LRAs are unable to induce 
substantive amounts of HIV-1 transcription with the notable exception of PKC agonists 
bryostatin-1-1 (7) and ingenol (8). However, LRA combinations in the same system are 
capable of inducing significant HIV-1 transcription (9-11). 
 The other half of the cure strategy deals with kiling newly reactivated infected 
CD4+ T cels. Recent experiments suggest that reactivation from latency is not enough to 
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induce cel death (12), and therefore there may be a need for immune mediated 
eradication. Expanded CD8+ T cel lines were able to clear reactivated latently infected 
resting CD4+ T cels folowing exposure to the HDAC inhibitor, vorinostat (13). 
However primary CD8+ T cels from patients on suppressive ART regimens that were 
pre-stimulated with overlapping Gag peptides were unable to consistently reduce the 
amount of HIV-1 mRNA induced from autologous resting CD4+ T cels that were 
activated with PMA and ionomycin (14). 
 The combination of romidepsin and bryostatin-1 has been shown to be one of the 
best inducers of latent HIV-1 in primary CD4+ T cels (9). However, bryostatin-1 has 
been showed to be involved in the modulation of NFkB and NFAT (15) and romidepsin 
is known to afect the function of NK cels and CD8+ T cels (16-17). Other HDAC 
inhibitors have furthermore been known to induce Treg cels in vitro (18-19). The 
immunomodulatory activity of the two drug classes thought to be most promising in cure 
eforts therefore needs to be further studied in the context of CD8+ T cel elimination of 
reactivated latently infected CD4+ T cels. 
 In this study, we sought to determine the ability of HIV-specific CD8+ T cels 
from patients with progressive HIV-1 disease on ART (chronic progressors) to kil HIV-
infected CD4+ T cels after treatment with LRAs. To elucidate the contribution of the 
drug treatments the HIV-specific response, suppression of infection was examined with 
elite suppressor CD8+ T cels that had been pre-treated with diferent LRAs, including an 
HDAC inhibitor, a bromodomain-containing protein 4 inhibitor, and multiple PKC 
agonists. Finaly, we examined the mechanisms that may have contributed to the efects 
	  55 





Donor blood samples. HIV-1 positive and HIV-1 negative blood samples were obtained 
from donors with writen, informed consent and handled according to a Johns Hopkins 
University IRB approved protocol. The chronic progressors studied were HIV-1 positive 
individuals who were started on suppressive ART therapy during chronic infection and 
have a viral load of <20 copies of HIV RNA/mL. Elite suppressors are patients who have 
maintained undetectable viral loads without antiretroviral therapy. The clinical 
characteristics of the patients are summarized in Table 1. 
Primary cel isolations. PBMCs were obtained from whole blood via Ficol-Paque 
PLUS gradient centrifugation (GE Healthcare Life Sciences). PBMCs underwent 
negative selection for CD4+ T cels using the MACS system (CD4 Isolation Kit, Miltenyi 
Biotech). Resting CD4+ T cels were further isolated from the bulk population by 
depleting CD25+, CD69+, and HLA-DR+ cels (CD25 microbeads, CD69 Isolation Kit, 
and HLA-DR microbeads; Miltenyi Biotech). When applicable, CD8+ T cels were 
obtained via positive selection from PBMCs (CD8 microbeads, Miltenyi Biotech) prior to 
any negative selection performed in experiments described below. 
Latency reactivation ex vivo and autologous suppression. Resting CD4+ T cels 
isolated from fresh blood samples from ART-suppressed individuals as described above 
(“Primary Cel Isolation”) were plated in 12-wel plates with 5 × 106 cels per replicate in 
non-stimulating media (RPMI 1640 + Glutamax, 10% FBS) and treated alone for six 
hours with the combination of bryostatin-1 (B, 10 nM; Sigma Aldrich) and romidepsin 
(R, 40 nM; Selleck Chemicals) in the presence of efavirenz (EFV, 10 µM) and raltegravir 
(RAL, 4 µM) to prevent new infection and more closely mimic in vivo conditions. CD8+ 
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T cels were isolated at this time as described above from PBMCs that had been 
previously stimulated for seven days in the presence of 100 U IL-2/mL and overlapping 
consensus Gag and Nef peptides (10 µg/mL; AIDS Reagent Database). At the conclusion 
of the six hours, the pre-stimulated CD8+ T cels were co-cultured with the resting CD4+ 
T cels at a 1:1 efector:target ratio and concentration of 5 × 106 cels/mL for another 18 h 
in the presence of B/R, EFV, and RAL at the same concentration as the initial treatment. 
The CD8+ T cels were not washed prior to co-culture with resting CD4+ T cels. In a 
second set of experiments, the CD8+ and CD4+ T cels were co-cultured together for 24 
h in the presence of B/R, EFV, and RAL. For each replicate, at the conclusion of the ful 
24 h, supernatant samples and the ful 5 × 106 cel samples were harvested and placed in 
TRIzol LS and TRIzol (Life Technologies), respectively, for the isolation of supernatant 
and cel-associated RNA. 
Isolation and quantification of cel-associated and supernatant HIV-1 mRNA. Cel-
associated and supernatant RNA were isolated, and the HIV-1 mRNA present in those 
samples was then quantified as previously described (7, 9, 14). Supernatant RNA samples 
were measured on a Roche LightCycler 480 Real-Time PCR thermocycler with TaqMan 
Fast Advanced Mastermix (Applied Biosystems) run as per manufacturer's instructions 
and the folowing primers: Forward (5′ → 3′) CAGATGCTGCATATAAGCAGCTG 
(9501–9523), Reverse (5′ → 3′) TTTTTTTTTTTTTTTTTTTTTTTTGAAGCAC (9629-
poly A). The probe used is as folows: (5′ → 3′) FAM-CCTGTACTGGGTCTCTCTGG-
MGB (9531–9550) (al nucleotide coordinates relative to HXB2 consensus sequence). 
The molecular standard curves used for the quantification were generated using serial 
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dilutions of a TOPO plasmid containing the final 352 nucleotides of the HIV-1 genomic 
RNA with the addition of 30 deoxyadenosines on the 5′ end to mimic the poly-A tail. 
Latency reactivation agents' efects on autologous suppression of ex vivo infection. 
Autologous bulk CD8+ and CD4+ T cels were freshly isolated from PBMCs from elite 
suppressors as described above (“Primary Cel Isolation”) for a modified version of a 
previously described HIV suppression assay (20). CD8+ T cels were treated for six hours 
in non-stimulating media (RPMI 1640 + Glutamax, 10% FBS) with either nothing, 
DMSO, romidepsin (40 nM), JQ1 (1 µM; Sigma Aldrich), vorinostat (335 nM), 
panobinostat (30 nM), bryostatin-1 at three concentrations (10 nM, 1 nM, 0.1 nM), or 
prostratin at two concentrations (1 µM, 0.3 µM; Sigma Aldrich) alone or in the 
combinations of romidepsin and bryostatin-1, romidepsin and prostratin, or bryostatin-1 
and JQ1 at those concentrations. Meanwhile, the bulk CD4+ T cels were spinoculated at 
1200 ×g for two hours at 37 °C with HIV-1NL4 − 3 ∆Env − GFP, a replication incompetent lab 
strain pseudovirus with env replaced with gfp and whose expression is controled by the 
HIV promoter. At the conclusion of the six-hour drug treatments, the drug was washed 
from the CD8+ T cels before the cels were added in a 1:1 efector:target ratio to the 
spinoculated CD4+ T cels. The cells co-cultured in nonstimulating media (RPMI 1640 + 
Glutamax, 10% FBS) were incubated for three days prior to FACS analysis. 
Bryostatin-1 treatment and its efects on cytokine production. PBMCs isolated from 
elite suppressors were plated at a concentration of 1 × 106 cels per mL in 48-wel plates 
and treated for six hours with nothing, DMSO, romidepsin (40 nM), bryostatin-1 (10 
nM), and the combination of romidepsin and bryostatin-1. After treatment, cells were 
washed and then re-plated as before in non-stimulating media (RPMI 1640 + Glutamax, 
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10% FBS). Al samples were cultured with Golgi Plug and Golgi Stop (BD Biosciences) 
as per manufacturer's instructions and 1 µg/mL of anti-CD28 and anti-CD49d antibodies 
(NA/LE anti-CD28 clone CD28.2, anti-CD49d clone 9F10; BD Biosciences). The no-
stimulation control had no additional treatment added, and the two stimulation conditions 
were incubated with 10 µg/mL overlapping consensus Gag peptides and 1 µg/mL anti-
CD3 for stimulation (NA/LE anti-CD3 clone HIT3a; BD Biosciences), respectively. 
General efects of latency reactivation agents on immune markers and cel death. 
PBMCs isolated from HIV-negative donor blood were plated at a concentration of 1 × 
106 cels per mL in 48-wel plates and treated for six hours with nothing, DMSO, 
romidepsin (40 nM), bryostatin-1 at three concentrations (10 nM, 1 nM, 0.1 nM), 
prostratin (0.3 µM), and the combination of romidepsin (40 nM) and bryostatin-1 (10 
nM). The doses of these drugs were selected based on the concentrations needed to 
reverse latency either alone or in combination (9). 40 nM of romidepsin is below the 
concentration of the plasma levels achieved in patients treated with this drug for 
lymphoma (21). Plasma bryostatin-1 levels of close to 1 nM have been achieved in 
patients receiving the highest tolerated dose of the drug (22). Two sets of cultures were 
set aside for analysis by FACS at six hours post-treatment and 18 hours post-treatment. 
For the rest of the cultures, cels were washed after six hours of drug treatment prior to 
replating in fresh plates at the same concentration of cels in non-stimulating media 
(RPMI 1640 + Glutamax, 10% FBS) either in the presence or absence of 1 µg/mL anti-
CD3/CD28 antibodies (NA/LE anti-CD3 clone HIT3a, anti-CD28 clone CD28.2; BD 
Biosciences) for an additional 1, 2, or 3 days before FACS analysis. 
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FACS analysis of suppression and immune markers. For the suppression experiments, 
samples were analyzed for infected CD4+ T cels by staining for CD3 (PacBlue, BD 
Biosciences), CD4 (BV605, Biolegend), and CD8 (APC-H7, BD Biosciences) and 
examining for the GFP+ (pseudovirus infected) cels. The amount of suppression was 
calculated by comparing the amount of infected CD4+ T cels with CD8+ T cel co-
culture to those without efector cel co-culture (% Suppression = [1 − (% GFP+ CD4+ T 
cels cultured with CD8+ T cels) / (% GFP+ CD4+ T cels without efectors)] × 100%). 
Intracelular cytokine expression was determined with the folowing panel: 
CD3·PacBlue, CD4·BV605, CD8·APC-H7, CD69·APC (Biolegend), IL-2·PE (BD 
Biosciences), TNFα·PE-Cy7 (BD Biosciences), IFNγ·PerCP-Cy5.5 (BD Biosciences), 
and Perforin-FITC (Cel Sciences). Immune markers and cel death were examined in the 
HIV-negative donors' cels via three staining panels (Panel A: CD3·APC-Cy7 
[Biolegend], CD4·BV605, CD8·APC [BD Biosciences], PD-1·FITC [Biolegend]; Panel 
B: CD3·PE [BD Biosciences], CD4·BV605, CD8·APC-H7, CD69·APC, 7-AAD [BD 
Biosciences], Annexin V·V450 [BD Biosciences]; Panel C: CD3·PacBlue, CD8·APC-
H7, CD69·BV605, CD160·PE [Biolegend], TIM-3·PE-Cy7 [Biolegend], 2B4·APC [BD 
Biosciences]). CD69, the exhaustion markers, and Annexin V expression are shown as 
raw data, but expression of CD3 is compared via MFI ratio (MFI ratio = [MFI of marker 
in treatment]/[MFI of marker in no treatment]). Al samples were run on a BD 
FACSCantoI flow cytometer and analyzed in FlowJo vX.0.7. 
Statistics. Statistical analyses performed for HIV-1 RNA (Fig. 1) were conducted using 
Wilcoxon matched-pair signed-rank test, the nonparametric alternative to the paired t-test 
as previously described (14). Descriptive statistics for other experiments are presented as 
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means and standard deviations. Comparisons of treatment groups to the control (NT) 
were conducted using repeated measures ANOVA model with adjusted pair-wise 
comparisons to NT via Dunnet's corection. Strength of evidence, threshold p-values, 
wil be presented as: ns (>0.05), * (<0.05), ** (<0.01), and *** (<0.001). Parametric 
methods were used due to the failure of nonparametric to detect significance for paired 
data with sample size less than six. Al statistics and graphics were performed with 




Ex vivo reactivation of latently infected CD4+ T Cels and CD8+ efector-mediated 
elimination 
 Resting CD4+ T cels from six ART-suppressed HIV-1+ individuals were treated 
with 10 nM bryostatin-1 and 40 nM romidepsin (B/R) for twenty-four hours to reactivate 
latent HIV-1 proviruses. A subset of samples from each of the individuals was further co-
cultured with autologous CD8+ T cels that had been previously cultured for 7 days in the 
presence of IL-2 and overlapping consensus Gag and Nef peptides to determine whether 
these immune efectors cels could eliminate latently infected cels. In a prior study we 
demonstrated that viral release occured as early as 6 h after resting CD4+ T cel 
stimulation (14), so the CD8+ T cels were added at 6 h to minimize their exposure to the 
latency reversal agents. In al six individuals, cel-associated HIV mRNA was increased 
by a median of 12.72-fold due to B/R treatment as compared to resting CD4+ T cels 
cultured in the absence of drugs (p < 0.0002, Fig. 1B). However, the co-culture of B/R-
treated resting CD4+ T cels with stimulated CD8+ T cels did not result in a significant 
decrease in the amount of HIV-1 mRNA, although three of the six individuals showed a 
trend towards a decrease in the amount of cel-associated HIV-1 mRNA (Fig. 1B). The 
efect of drugs and CD8+ T cels on the release of virus into culture supernatant was also 
examined. HIV-1 mRNA present in culture supernatant increased significantly from an 
undetectable baseline (500 copies/mL) folowing B/R treatment to a median of 5281.6 
copies/ml (p < 0.001), and there was no significant diference seen when the B/R-treated 
CD4+ T cels were co-cultured with CD8+ T cels (Fig. 1C). Of the six individuals, only 
CP25 had a decrease in both cel-associated and supernatant HIV-1 mRNA due to co-
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culture of B/R-treated resting CD4+ T cels with CD8+ T cels (Fig. 1C). We repeated the 
experiments with CD8+ T cels present at the time point 0 to ensure that the failure to 
eliminate reactivated CD4+ T cels was not due to early transcription and translation in 
the absence of the efector cels. However, there was stil no significant decrease in either 
intracelular (Fig. 1D) or extracelular mRNA expression (Fig. 1E) when the stimulated 
CD4+ T cels were co-cultured with CD8+ T cels. 
Elite suppressor CD8+ T cel responses after ex vivo treatment with latency 
reactivating agents 
 To elucidate whether or not the lack of an efective response to reactivated HIV-1 
from latently infected CD4+ T cels in the chronic progressors was due to host factors or 
the drugs themselves we studied the efects of the drugs on HIV-specific CD8+ T cel 
responses. Elite suppressors were used for these studies, as they are known to have 
qualitatively superior HIV-specific CD8+ T cel responses as compared to the average 
chronic progressor (23-27). CD4+ T cels from ES were infected with replication 
incompetent HIV-1NL4 − 3 ∆Env − GFP pseudovirus and co-cultured with autologous CD8+ T 
cels that had been previously incubated with a variety of latency reversing agents 
(LRAs), as previously described (20, 28). DMSO, the vehicle for al the drugs, had no 
efect on the CD8+ T cel-mediated suppression as compared to no treatment (Fig. 2A–E 
). Romidepsin (40 nM throughout) alone and bryostatin-1 at either 10 nM or 1 nM 
significantly inhibited the ability of elite suppressor CD8 T cels to suppress infection as 
compared to untreated CD8+ T cels (Fig. 2A). The combination of romidepsin and al 
three concentrations of bryostatin-1 tested (10 nM and 1 nM significantly inhibited 
suppression as compared to untreated CD8+ T cels, and the combinations of romidepsin 
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and bryostatin-1 at either 10 nM or 1 nM were much more inhibitory than either drug 
alone, with an 81.8% and 84.0% reduction in the amount of suppression seen for the 
combination of bryostatin at 10 nM and romidepsin from each drug alone, respectively, 
and 72.6% and 70.8% reduction for the combination of bryostatin at 10 nM and 
romidepsin from each alone. 
 In order to determine whether the inhibition of suppression is unique to 
bryostatin-1 or is a feature of PKC agonists, CD8+ T cels from elite suppressors were 
also treated with prostratin at either 1 µM or 0.3 µM alone or in conjunction with 
romidepsin. As opposed to bryostatin-1, prostratin alone at either concentration had no 
significant efect upon the suppressive capacity of the CD8+ T cels (Fig. 2B). The 
combination of prostratin at 1 µM and 0.3 µM with romidepsin significantly inhibited the 
suppression of infection (p < 0.0001), but this inhibition was very similar to the inhibition 
seen by romidepsin alone (Fig. 2B). 
 The efect of JQ1, a bromodomain-containing protein 4 inhibitor, was also 
examined alone and in conjunction with bryostatin-1 or prostratin as these combinations 
of drugs have also been shown to be efective at reversing latency in vitro (9). Treatment 
of CD8+ T cels with JQ1 (1 µM) alone resulted in a slight, nonsignificant decrease in 
CD8+ T cel suppression (Fig. 2C). A significant decrease in CD8+ T cel-mediated 
suppression was seen when JQ1 was given in combination with bryostatin-1 at 10 nM 
and 1 nM (p < 0.001 for both), but this was not significantly diferent from the inhibition 
seen with bryostatin-1 alone at either concentration (Fig. 2C). In contrast, the 
combination of prostratin and JQ-1 did not have a significant efect on the CD8+ T cel 
function (Fig. 2D). 
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 In order to determine whether romidepsin's efect on CD8+ T cel suppressive 
activity was unique to this drug or a feature of al HDAC inhibitors, we compared the 
efects of romidepsin vorionostat and panobinostat on ES CD8+ T cel function. The 
concentrations used were based on concentrations that had been shown to be efective in 
prior studies (9, 29) and were similar to levels that have been achieved in vivo (21, 29-
31). While romidepsin and panobinostat had significant inhibitory efects on ES CD8+ T 
cels, vorinostat did not cause significant suppression (Fig. 2E). These results are similar 
to results obtained with HIV-specific CD8+ T cel clones (17). 
CD8+ T cel cytokine production after LRA treatment 
 We next sought to find a mechanism for the inhibition of suppression due to 
bryostatin-1 treatment and first examined the ability of elite suppressor HIV-specific 
CD8+ T cels to produce cytokines after a 6-hour treatment with bryostatin-1 and 
romidepsin folowed by 12-h of stimulation with either Gag peptides or anti-CD3 and 
CD28 monoclonal antibodies. Bryostatin-1 treatment alone tended to cause an increase in 
the percentage of cels that produced TNF-α, both TNF-α and IFN-γ, and IL-2 folowing 
anti-CD3/CD28 stimulation (for IL-2, p < 0.05; Fig. 3B). In contrast, the B/R 
combination caused an increase in the percentage of cytokine-producing CD8+ T cels at 
baseline (IFN-γ, TNF-α, and IFN-γ and TNF-α), and folowing stimulation with Gag 
peptides (TNF-α; p < 0.05) and anti-CD3/CD28 monoclonal antibodies (TNF-α, TNF-α 
and IFN-γ, and IL-2; for IL-2 only,p < 0.05). Thus it appears that a decrease in cytokine 
expression was not the mechanism of suppression of CD8+ T cel antiviral activity. 
PKC agonist efects upon cel death and exhaustion in T cels 
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 To further elucidate the mechanisms by which the LRAs afected CD8+ T cel 
function, CD8+ T cels from HIV-negative donors were interogated for the amount of 
cel death induced by drug treatment as determined by Annexin V expression. For both 6-
hour and 18-hour treatments with LRAs, the combination B/R treatment induced a trend 
towards a higher amount of cel death than cels treated with DMSO (not shown). To 
examine the efects of the LRAs on cel viability over time, cels were treated for six 
hours before being washed and cultured for an additional three days in the absence of 
stimulation. For this time course, 10 nM bryostatin-1-treated CD8+ T cels had a trend 
towards more cel death on day 1 and significantly more on day 2 (p < 0.05). A trend 
towards higher cel death was likewise observed in B/R-treated CD8+ T cels (Fig. 4B). 
To model the efect of the LRAs on activated CD8+ T cels, CD8+ T cels treated with 10 
nM bryostatin-1 and B/R for six hours were stimulated with anti-CD3/CD28 antibodies 
for an additional two days. Cels treated with anti-CD3/CD28 generaly had increased 
cel death compared to CD8+ T cels that did not receive this treatment, but only 
bryostatin-1 and B/R treatment of anti-CD3 activated cels caused a significant increase 
in cel death compared to antibody treatment alone as determined by annexin V 
expression (Day 1, bryostatin-1: p < 0.05; Day 2, B/R: p < 0.05; Fig. 4B) and supported 
by trends with annexin V and 7-AAD co-expression. 
 We also examined the expression of the exhaustion markers PD-1, Tim-3, 2B4, 
and CD160 folowing 6 h of treatment with the diferent drugs as a potential cause of the 
observed inhibition of CD8+ T cel responses. Bryostatin-1 at 10 nM and B/R induced 
modest but significant increases in PD-1, TIM-3 and 2B4 expression at diferent time 
points over a 3 day time period (example of PD-1 gating shown in Supplementary Fig. 
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1A; Fig. 5A–C). In order to determine the efects of the LRAs on activated cels, we 
looked at the expression of these exhaustion markers on cels that were exposed to drugs 
for 6 h and then stimulated with CD3 and CD28 specific antibodies. PD-1, CD160 and 
2B4 expression levels were significantly increased in activated cels that were treated 
with bryostatin-1 or B/R on day 2 whereas romidepsin tended to increase CD160 
expression on the activated cels at the same time point (Fig. 6A–C ). Furthermore, 
bryostatin-1 also significantly PD-1 expression in the stimulated cels on day 2 as 
measured by ratio of the mean fluorescence intensity of the treated cels to that of the 
untreated cels (p < 0.05; Supplementary Fig. 1). 
 In order to determine whether the expression of the exhaustion markers was just a 
marker of T cel activation we looked at CD69 expression on CD8+ T cels treated with 
LRAs. Bryostatin-1 treatment has been shown to induce CD69 on resting CD4+ T cels 
(9), and we found very high levels of this early activation marker on CD8+ T cels that 
were treated with 10 nM and 1 nM bryostatin-1, B/R, and prostratin (Fig. 7). PD-1, 2B4 
and TIM-3 expression was not upregulated on prostratin-treated cels, implying that the 
expression of these exhaustion markers was not just a reflection of partial activation 
although further experiments are needed to verify this. 
PKC agonist-induced modulation of TCR-related markers 
 PKC agonists such as PMA have been known to downregulate CD3 (32), which 
has the potential to inhibit T cel responses. In order to determine whether LRA treatment 
had an efect on CD3 expression, we examined the change in the mean fluorescence 
intensity (MFI) of this marker. CD8+ T cels treated with bryostatin-1 at 10 nM and 1 nM 
and B/R had a significant decrease in CD3 expression after six hours of treatment 
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(bryostatin-1: p < 0.01 at 10 nM, p < 0.05 at 1 nM; B/R: p < 0.01; Fig. 8A ). However, 
after 18 h of treatment, bryostatin-1 at 10 nM and 1 nM, the B/R combination, and 
prostratin alone cause significant decreases in CD3 expression compared to untreated 
cels (p < 0.0001 for 10 nM bryostatin-1 and B/R; p < 0.001 for bryostatin-1 at 1 nM and 
prostratin; Fig. 8A). For CD8+ T cels treated for six hours and then cultured for a day in 
the absence of treatment, bryostatin-1 at 10 nM and 1 nM as wel as B/R continued to 
cause a significant decrease in CD3 expression (bryostatin-1: p < 0.01, p < 0.05, 
respectively; B/R: p < 0.001; Fig. 8B). Unlike bryostatin-1 treatment alone, however, the 
efect of B/R on CD3 expression maintained at day 1 (Fig. 8A,B). Overal, while 
bryostatin-1 has an efect on CD3 expression alone, the combination of bryostatin-1 with 




 Curent HIV-1 cure strategies seek to eliminate the latent reservoir by specificaly 
activating HIV-1 so the immune system can clear the latently infected cels. The most 
promising latency reactivating agent (LRA) regimens in vitro thus far appear to be 
combinations of HDAC inhibitors (HDACi) and PKC agonists (9). However, some of 
these drugs have previously been suggested to have immunomodulatory efects (17; 
reviewed in 33-34). In this study, we confirm that the combination of bryostatin-1 and 
romidepsin is efective in reversing latency, however we found that even folowing 
stimulation with high concentrations of IL-2 and Gag and Nef consensus peptides, CD8+ 
T cels from fuly suppressed chronic progressors were unable to reduce the amount of 
HIV-1 mRNA associated with CD4+ T cels or prevent release of virions from these cels 
in the context of bryostatin-1 and romidepsin treatment. One limitation of our study is 
that we did not measure actual viral protein production or antigen presentation folowing 
latency reversal. It is possible that some of the mRNA we measured is defective and did 
not lead to the synthesis of functional proteins that could be recognized by CD8+ T cels. 
Another possibility is that the efects of the LRAs may be short lived in vivo since HIV-
specific CD8+ T cels from patients treated with vorinostat (13) and romidepsin (35) 
appeared to be functional in ex vivo studies, but even a short term efect could be 
important for viral clearance. Another limitation is the relatively smal number of patients 
studied in this manuscript. 
 In a prior study, autologous ex vivo expanded virus-specific cytototoxic T 
lymphocytes, but not unexpanded CD8+ T cels, from HIV infected patients were able to 
significantly reduce the number of latently infected cels folowing reversal with 
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vorinostat (13). The discrepancy between that study and our findings could potentialy be 
explained by the fact that vorinostat has much less of an efect of on CD8+ T cels than 
did romidepsin, bryostatin-1 and the combination of the 2 drugs. Chronic progressors' 
primary CD8+ T cels are generaly not efective in controling HIV-1 replication 
(reviewed in 36), which may also partialy account for observed results. In order to 
determine other potential causes, we examined the efect of four separate LRAs alone and 
in combination on the HIV-specific CD8+ T cel response of elite suppressors. 
 Elite suppressors are HIV-positive individuals who have viral loads of <50 copies 
of HIV-1 RNA per mililiter in the absence of antiretroviral therapy (37). These 
individuals are known to have qualitatively superior HIV-specific CD8+ T cel responses 
than chronic progressors (23-27). We performed suppression assays with cels from four 
elite suppressors and found that untreated CD8+ T cels were able to suppress infection 
efectively but that treatment with romidepsin (40 nM) or bryostatin-1 (10 nM) alone 
significantly inhibited this suppression by nearly 50%. The combination of the two LRAs 
at those concentrations fuly ablated the suppression in two individuals and otherwise 
significantly reduced the average suppression by 90% suggesting that the two drugs may 
have an additive, negative efect (Fig. 2A).  Interestingly, prostratin, another PKC 
agonist did not have an inhibitory efect on CD8+ T cel mediated suppression, 
suggesting that the efect on CD8+ T cel function may not be a feature of the entire class 
of drugs. HDAC inhibitors such as romidepsin and panobinostat have been shown to 
selectively cause the death of activated cels (17), and PKC agonists such as bryostatin-1, 
prostratin, and PMA are known to cause partial activation in T cels (38-40), with 
bryostatin-1 specificaly acting as a TLR-4 ligand (41). We therefore combined 
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romidepsin with prostratin, which also induced partial activation as determined by CD69 
expression, to determine if the additive negative efect seen when bryostatin-1 and 
romidepsin were combined was a general efect of adding an HDAC inhibitor to a PKC 
agonist. Interestingly, the combination had an equal amount of suppression as romidepsin 
alone (Fig. 2B). JQ1 (1 µM), a bromodomain-containing protein 4 inhibitor, also had 
minimal efect on CD8+ T cel mediated suppression and did not appear to have an 
additive inhibitory efect when it was combined with bryostatin-1. The combination of 
prostratin and JQ1 has also recently shown to be efective (9) and these drugs together 
did not have an adverse efect on CD8+ T cel function. 
 In order to determine the mechanism for the inhibition of suppression seen with 
romidepsin, bryostatin-1, and the combination of the two, we examined the LRA 
treatment-dependent toxicity and induction of exhaustion on CD8+ T cels. Bryostatin-1 
treatment at 10 nM causes an increase in cel death and PD-1 expression, and combined 
bryostatin-1 and romidepsin treatment more closely mimics the efects of bryostatin-1 
treatment as compared to romidepsin treatment, suggesting that the phenomena are 
bryostatin-1-mediated. The increased cel death and exhaustion shortly after treatment 
with 10 nM bryostatin-1 likely contributes to the CD8+ T cel dysfunction in the 
suppression assays, given that CD8+ T cel kiling of HIV-1 infected CD4+ T cels can 
occur within an hour (26). 
 PKC agonists are known to downregulate CD3 (32) as wel as CD4 (42-45). 
Downregulation of CD3-TCR complexes as wel as the coreceptors CD4 and CD8 may 
inhibit the ability of efector T cels to respond to their cognate antigen, leading us to 
examine the expression of these markers in T cels. We found that bryostatin-1 treatment 
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caused transient downregulation of CD3 in unstimulated CD8+ T cels, but treatment 
with bryostatin-1 and romidepsin prolonged this efect. Even a transient efect may be 
important because we have previously shown that virion release from latently infected 
CD4+ T cels may occur as early as 6 h after activation (14), and therefore a quick 
immune response wil be needed to eliminate reactivated CD4+ T cels. 
 In summary, we have shown that the HDACi/PKC agonist LRA combination of 
bryostatin-1 and romidepsin causes marked inhibition of the HIV-specific CD8+ T cel 
response, as do both drugs alone. The inhibition of the T cel response by bryostatin-1 
may be due an increase in T cel death and exhaustion marker expression as wel as a 
downregulation of CD3, resulting in a decreased ability of T cels to respond to stimuli. 
The combination of romidepsin with bryostatin-1 furthermore causes a more severe and 
possibly longer-lasting downregulation phenotype, potentialy contributing to the more 
severe inhibition of the T cel response. Any HIV-1 cure strategy involving LRA-based 
reactivation wil likely depend upon the immune response to eliminate any latently 
infected cels, but given the range of negative efects the LRAs have upon the immune 
response alone and in combination, each potential LRA therapy should be examined for 
its broad efects on adaptive immunity before use in the context of HIV-1 cure. 
Combinations of latency reversal agents such as prostratin and JQ1 that together do not 
have significant efects on HIV-specific immune responses may be the most efective 
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 While curent treatment for HIV-1 extends the lives of milions around the world, 
the need for both a cure and a vaccine remain. The curent strategy for eradication would 
require the use of latency reactivating agents (LRAs) to reactivate the latent HIV-1 
present in CD4+ T cels. However, despite the fact that many LRAs in combination are 
capable of robustly inducing HIV mRNA expression (1), the efects of the LRAs upon 
the adaptive immune system vary from causing no change to complete ablation of the 
suppressive capacity of the CD8+ T cel response of elite suppressors (2). The 
mechanism behind the inhibition of the CD8+ T cel response caused by bryostatin-1 
appears to be an increase in cel death, the downregulation of CD3, and the increase in 
expression of exhaustion markers (2). HDAC inhibitors alone have also been seen to 
cause CD8+ T cel efector dysfunction in vitro (3), and the combination of bryostatin-1 
and romidepsin causes a detrimental efect upon the CD8+ T cel response that was worse 
than either drug alone (2). Despite the fact that the combination of bryostatin-1 and 
romidepsin induce reactivation in resting CD4+ T cels, the prevention of an efective 
CD8+ T cel response due to the drug treatment undermines the premise of the “shock 
and kil” strategy. 
 While multiple HDAC inhibitors and bryostatin-1 had detrimental efects upon 
the CD8+ T cel response, not al LRAs alone or in combination do (2). The combination 
of JQ1 and prostratin appear to keep the “kil” component of “shock and kil” intact (2). 
However, the CD8+ T cel response is not always capable of eliminating reactivated 
primary latently infected CD4+ T cels in al HIV-positive individuals, even when PMA 
and ionomycin are used to induce HIV mRNA expression and are removed from culture 
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prior to the addition of efectors (4). Very few of the chronic progressors examined and 
only half of the viremic controlers exhibited this capacity (4), but a therapeutic vaccine 
that induced a CD8+ T cel response like what was seen in with the CMV-based SIV 
vaccine (5) might be able to properly boost the T cel responses of those individuals 
whose responses were inadequate. 
 Any infection that remains within other celular reservoirs, such as macrophages, 
might also be taken care of by a therapeutic vaccine. The CD8+ T cel response of elite 
suppressors can kil infected monocyte-derived macrophages (MDMs), and CD4+ T cels 
are also capable of suppressing infection of the MDMs (6). Macrophages are found in 
many tissues, including the brain (7), and although they may be of less concern when 
HIV-positive individuals are treated with cART, the ability of the adaptive immune 
response to eliminate any infected macrophages would be a concern for both post-cure, 
assuming complete eradication is unlikely, as wel as for any T-cel based vaccine. Given 
that CD4+ T cels that come in physical contact with infected macrophages are eficiently 
infected (6), the kiling of the macrophages would be necessary to prevent any reseeding 
of the latent reservoir post any curative strategies that are unable to induce a sterilizing 
cure before cART cessation. 
 An immeasurable amount of progress has been made in the treatment of HIV-1 
infection since its discovery in 1981 (8). With the advent of cART in the mid-nineties, 
HIV-1 infection went from incurable and almost always fatal to a chronic condition (9). 
In the twenty years since, only one individual has ever been cured of HIV-1 (10), and no 
vaccine yet exists. The “shock and kil” cure strategy has promise, but to succeed, it wil 
likely need to be used in conjunction with some sort of therapeutic vaccine or 
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immunomodulatory treatment. Any single LRA or combination thereof should be 
examined for their efects upon the adaptive immune system before being used clinicaly 
in order to minimize risk to the patients and maximize the likelihood that both the 
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Table 1. Clinical characteristics of study patients. 
 
aART, antiretroviral therapy. 
bThe patient is HLA-B*08/44 positive. 
cThe patient usualy has a viral load of <75 copies/ml in the branched DNA assay. 
dND, not determined. 




Figure 1. ES macrophages are infected as wel as HD and CP macrophages. (A) 
Individual HIV-1 growth curves for ESs (n = 12), CPs (n = 11), and HDs (n = 19) whose 
MDMs were infected by spinoculation of HIVBaL; (B) average ± standard eror virus 
production by MDMs from the aforementioned groups; (C) HIV-1 replication in MDMs 




Figure 2. CD8+ T cels from ESs are more efective than CD8+ T cels from CPs at 
inhibiting viral replication in macrophages. MDMs were infected with 500 ng HIVBaL per 
106 cels and cultured with CD8+ T cels in a 1:2 ratio, and the percent inhibition was 
calculated by measuring the p24 content of the supernatant via ELISA. (A) Inhibition of 
viral production on days 5 and 7 for ES (n = 9), CP (n = 10), and HD (n = 18) MDMs, 
with the medians indicated by horizontal bars; (B) distribution of the inhibitory responses 
in each subset on day 7; (C) CD8-mediated inhibition of virus production by CD4+ T cel 
and macrophage targets (n = 3 [cels from ESs 6, 22, and 24]); (D) the inhibitory abilities 
of CD8+ T cels when isolated via positive and negative selection are equal (n = 3 [cels 




Figure 3. CD4+ T cels from ESs are not more efective than CD4+ T cels from CPs at 
inhibiting viral replication in macrophages. MDMs were infected with 500 ng HIVBaL per 
106 cels and cultured with CD4+ T cels in a 1:2 ratio, and the percent inhibition was 
calculated by measuring the p24 content of the supernatant via ELISA. (A) Inhibition of 
viral production on days 5 and 7 for ES (n = 9), CP (n = 10), and HD (n = 18) MDMs, 
with the medians indicated by horizontal bars; (B) distribution of the inhibitory responses 




Figure 4. CD8+ T cels from ESs are more efective than CD4+ T cels at inhibiting viral 
replication in macrophages. MDMs were infected with 500 ng HIVBaL per 10
6 cels and 
cultured with CD4+ or CD8+ T cels in a 1:2 ratio. Infection was measured by p24 ELISA 




Figure 5. CD4+ T cel-mediated inhibition of viral production is partialy soluble factor 
mediated, while CD8+ T cel-mediated inhibition is contact dependent. MDMs infected 
with HIVBaL were cocultured with CD4
+ or CD8+ T cels in a 1:1 efector cel/target cel 
ratio either directly or with separation in transwels. Viral production was measured by 
p24 ELISA. (A) CD4+ efector-mediated inhibition of virus production by two ES 
individuals, with the CD4+ response shown; (B) CD4+ efector-mediated inhibition (n = 
5); (C) CD8+ efector-mediated inhibition of virus production by two ES individuals, 




Figure 6. Stimulated ES CD8+ T cels kil infected macrophages. Stimulated and 
unstimulated efector cels were added to cultures of MDMs that had been infected with 
HIVBaL a week earlier. Target cel kiling was determined with the Cytotox-96 
nonradioactive cytotoxicity assay. (A) Comparison of the kiling ability of primary and 
stimulated (Stim.) efector cels from ESs (n = 6), CPs (n = 5), and HDs (n = 5) 24 h after 
efector cel addition; (B) comparison of the ability of CD4 and CD8 efector cels from 




Figure 7. CD4+ efectors from ESs, CPs, and HDs are infected by target MDMs. MDMs 
infected with HIVBaL were cocultured with CD4
+ T cels at 1:1, 1:2, and 1:4 efector 
cel/target cel (E:T) ratios immediately after spinoculation. (A) CD4+ efector infection 
on day 7 determined via intracelular Gag positivity for 8 ESs, 6 CPs, and 10 HDs (data 
are averages ± standard erors); (B) infection of CD4+ T cel efectors from ESs (n = 5) 
and HDs (n = 5) over time, with medians indicated as horizontal bars; (C) corelation 
between infection of CD4+ cels and their ability to inhibit infection at a 1:2 ratio for the 
8 ESs and 5 CPs on day 7; (D) corelation between infection of CD4+ cels and their 
ability to inhibit infection at a 1:2 ratio for the 8 ESs alone; (E) corelation between 

















CP9 991 <20 8 TDF, FTC, ELV/c 
CP10 424 <20 7 RAL, EFV 
CP11 1,001 <20 7 TDF, FTC, DRV/r 
CP12 802 <20 2 3TC, RAL, EFV 
CP13 744 <20 2 TDF, FTC, ELV/c 
CP15 896 <20 7 TDF, FTC, ATV/r 
CP16 946 <20 4 3TC, ABC, ATV/r 
CP17 671 <20 4 TDF, FTC, DRV/r 
CP18 1,084 <20 4 TDF, FTC, EFV 
CP20 405 <20 8 TDF, FTC, ATV/r 











CP22 1,210 <20 4 TDF, FTC, DRV/r 
CP23 448 <20 1 ABC, 3TC, ATV 
CP24 657 <20 1 TDF, FTC, RAL 
CP25 418 <20 4 TDF, FTC, RAL 
CP26 964 <20 8 TDF, FTC, RAL 
CP27 725 <20 6 TDF, FTC, ELV/c 
CP28 722 <20 4 TDF, FTC, EFV 
CP29 715 <20 5 TDF, FTC, EFV 
CP30 471 <20 13 TDF, FTC, EFV 
VC1 1,190 80 NA NA 
VC10 441 335 NA NA 











VC12 1,254 1,133 NA NA 
aThe subjects were chronic progressors (CPs) and viremic controlers (VCs). 
bNA, not applicable. 
cNucleoside reverse transcriptase inhibitors (NRTI) tenofovir (TFV), emricitabine (FTC), 
lamivudine (3TC), and abacavir (ABC) were used. Nonnucleoside reverse transcriptase 
inhibitors (NNRTI) efavirenz (EFV) and rilpivarine (RPV) were used. Integrase 
inhibitors elvitegravir (ELV) and raltegravir (RAL) and protease inhibitors darunavir 
(DRV), atazanavir (ATV), and ritonavir (r) were used. The boosting agent cobicistat (c) 





Figure 1. Resting CD4+ T cels from HIV+ individuals produce virions in supernatant by 
6 h postreatment with PMA and ionomycin. Primary, resting CD4+ T cels from chronic 
progressors were treated with PMA and ionomycin for 6 h in the presence of raltegravir 
and efavirenz throughout. RNA isolated from culture supernatant was converted to 
cDNA, and HIV-1 mRNA was quantified via quantitative PCR (qPCR). Quantification of 
extracelular HIV-1 mRNA in culture supernatant at baseline, 0 to 6, and 6 to 24 h is 
shown for each donor. Solid symbols represent detectable RNA, and open symbols 
represent undetectable RNA levels. The dashed line represents the lower limit of 































































































































































































































































































































































































































































































































































Figure 2. HIV-1 mRNA is upregulated in primary resting CD4+ T cels 1 h 
poststimulation with PMA and ionomycin. Primary, resting CD4+ T cels were treated 
with PMA and ionomycin in the presence of raltegravir and efavirenz for 6 h with 
supernatant and celular samples taken before and 1, 3, and 6 h after initiation of 
stimulation. Intracelular and supernatant RNA was isolated with TRIzol and converted to 
cDNA, of which the HIV-1 mRNA was then quantified via qPCR. Intracelular HIV-1 
mRNA is upregulated in vitro after 1 h of PMA and ionomycin treatment. Solid symbols 
represent detectable RNA, and open symbols represent undetectable RNA levels. The 


































































































































































































































































































Figure 3. Autologous, Gag-stimulated CD8+ T cels are not efective in reducing 
intracelular HIV-1 mRNA in CD4+ T cels from chronic progressors. Primary, resting 
CD4+ T cels were treated with PMA and ionomycin in the presence of raltegravir and 
efavirenz for 6 h before coculture with CD8+ T cels prestimulated for a week with 
overlapping Gag peptides for 18 h. (A) Intracelular HIV-1 mRNA at 24 h after initiation 
of stimulation. (B) Median intracelular HIV-1 mRNA in cels with three diferent 
treatments with statistics coresponding to the entire data set. The three treatments were 
no stimulation (NS) (control), PMA and ionomycin treatment only (PMA/i), and PMA 
and ionomycin treatment with CD8+ T cel coculture (PMA/i + CD8). Solid symbols 




Figure 4. Autologous, Gag-stimulated CD8+ T cels are capable of reducing intracelular 
HIV-1 mRNA in CD4+ T cels from viremic controlers. Primary, resting CD4+ T cels 
were treated with PMA and ionomycin in the presence of raltegravir and efavirenz for 6 h 
before coculture for 18 h with CD8+ T cels prestimulated for a week with overlapping 
Gag peptides. Intracelular HIV-1 mRNA was measured by qPCR at 24 h after initiation 
of stimulation for each individual. NS = No stimulation. PMA/i = PMA and ionomycin 
treatment only. PMA/i + CD8 = PMA and ionomycin treatment and CD8+ T cell 
coculture. Solid symbols represent detectable RNA, and unfiled symbols represent 
undetectable RNA levels. The dashed line represents the limit of detection (20.4 copies 






Table 1.Clinical characteristics of the chronic progressors studied. 
Subject 
Current 
CD4+ T cel 
count 
Nadir CD4+ 





regiment HLA-A HLA-B 
CP8 
424 18 8 years 3TC, RAL 
EFV 
1, 68 57, 58 
CP9 
991 190 8 years TDF, FTC, 
DRV/c 
34, 68 58, 81 
CP11 
1032 177 8 years TDF, FTC, 
DRV/r 
2, 11 25, 57 
CP 14 




921 203 5 years 3TC, ABC, 
DTG 
29, 20 42, 81 
CP25 
584 NA 4 years TDF, FTC, 
RAL 
3, 30 8, 42 
ES 3 1149 NA NA NA 25, 68 51, 57 
ES 6 601 NA NA NA 23 15, 57 
ES 9 798 NA NA NA 2, 30 27, 57 
ES 22 1033 NA NA NA 30, 31 15, 57 
ES 24 1742 NA NA NA 24, 30 7, 57 
ES 31 1236 NA NA NA 3 27, 58 
3TC: lamivudine, ABC: abacavir, FTC: emtricitabine, TDF: tenofovir, DTG: dolutegravir, EFV: 
efavirenz, RAL: raltegravir, DRV/c: cobicistat boosted darunavir, DRV/r: ritonavir boosted 
darunavir. NA: Not applicable. 
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Figure 1. Nef- and Gag-stimulated CD8+ T cels from chronic progressors are not 
capable of eliminating newly-reactivated autologous CD4+ T cels folowing bryostatin-
1/romidepsin-treatment. A) Schematic of methods. Blue arows indicate methods 
common to both experiments, red arows indicate methods for Fig. 1B and C, and green 
arows indicate methods for Fig. 1D and E. B) Level of cel-associated HIV-1 mRNA 
seen with no stimulation (NS), treatment with bryostatin-1/romidepsin (B/R) or treatment 
with B/R and co-culture with CD8+ T cels for 18 h. No significance is indicated by n.s., 
and the listed p-value indicates the level of significance as determined by a Wilcoxon 
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signed rank test for significance. C) Level of HIV-1 mRNA present in culture supernatant 
for 6-hour drug treatment folowed by 18-hour CD8+ T cel co-culture. Doted line 
indicates the level of detection (500 copies HIV mRNA/mL). The listed p-value indicates 
the level of significance as determined by a Wilcoxon signed rank test for significance. 
D) Cel-associated HIV mRNA from 24-hour drug treatment and CD8+ T cel co-culture 
with resting CD4+ T cels. The listed p-value indicates the level of significance as 
determined by a Wilcoxon signed rank test for significance. E) Supernatant HIV mRNA 
from 24-hour drug treatment and CD8+ T cel co-culture with resting CD4+ T cels. The 
listed p-value indicates the level of significance as determined by a Wilcoxon signed rank 
test for significance. Doted line indicates the level of detection (100 copies HIV 





Figure 2. Elite suppressor CD8+ T cel responses are inhibited by bryostatin-1 and 
romidepsin alone and in combination. CD8+ T cels from 4 elite suppressors were 
preincubated with the indicated LRAs for six hours prior to the addition to autologous 
CD4+ T cels infected with lab strain HIV-1 pseudovirus in a 1:1 efector:target ratio and 
the percent suppression of viral replication was determined. Triplicates were performed 
and the mean values are shown for each individual. For panels D and E, data from 2 
separate experiments with cels from ES6, ES22, and ES24 were averaged, and data from 
an additional elite suppressor was included. A) Comparison of bryostatin-1 and 
romidepsin treatments. B) Comparison of prostratin and romidepsin treatments. C) 
Comparison of bryostatin-1 and JQ1 treatments. D) Comparison of prostratin and JQ1 
treatment. E) Comparison of romidepsin and other HDAC inhibitors. One-way repeated 
measures ANOVAs were used to determine significance for each of the two sets of 
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experiments. Symbols directly above treatments indicate diferences from NT, no 




Figure 3. Production of IFN-γ, TNF-α, and IL-2 by CD8+ T cels increases with 
bryostatin-1 treatment. IFN-γ (A), TNF-α (B), simultaneous IFN-γ and TNF-α (C), and 
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IL-2 (D) production in unstimulated (NS), Gag-peptide stimulated, and anti-CD3/CD28 
stimulated CD8+ T cels is shown for each of three elite suppressors with the mean ± 
standard eror. Significance was determined via a series of one-way repeated measures 
ANOVAs examining each of the twelve conditions separately, and level of significance 




Figure 4. Bryostatin-1 and bryostatin-1/romidepsin combination treatments cause an 
increase in CD8+ T cel death. Eight HIV negative donors' PBMCs were treated with 
LRAs and examined for annexin V expression on CD8+ T cels. A) Annexin V 
expression in CD8+ T cels treated with drug for 6 h and then cultured for three days 
post-treatment in non-stimulating media. B) Annexin V expression in CD8+ T cels 
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treated with drug for 6 h and then stimulated with anti-CD3/CD28 for either one or two 
days afterward. C) Annexin V and 7-AAD expression in CD8+ T cels treated with drug 
for 6 h and then stimulated with anti-CD3/CD28 for either one or two days afterward. 
One-way repeated measures ANOVAs were used to calculate significance, and the level 
of significance indicated is in comparison to the no treatment condition. * p < 0.05, ** p 






Figure 5. Bryostatin-1 treatment induces an increase in exhaustion marker expression in 
unstimulated CD8+ T cels. Eight HIV-negative donors' PBMCs were treated with LRAs 
and examined for PD-1 expression on CD8+ T cels, and four donors' PBMCs were 
examined for TIM-3, 2B4, and CD160 expression. A) PD-1 expression in CD8+ T cels 
treated with drug for 6 h and then incubated in non-stimulating media for an additional 
three days. B) TIM-3 expression. C) 2B4 expression. D) CD160 expression. The level of 




Figure 6. Bryostatin-1 treatment induces an increase in exhaustion marker expression in 
stimulated CD8+ T cels. Eight HIV-negative donors' PBMCs were treated with LRAs 
and examined for PD-1 expression on CD8+ T cels, and four donors' PBMCs were 
examined for TIM-3, 2B4, and CD160 expression. A) PD-1 expression in CD8+ T cels 
treated with drug for 6 h and then incubated with anti-CD3/CD28 antibodies for an 
additional two days. B) 2B4 expression. C) CD160 expression. D) TIM-3 expression. The 





Figure 7. CD69 expression is upregulated due to treatment with PKC agonists. Eight 
HIV-negative donors' PBMCs were treated with LRAs for 6 h before being washed and 
then cultured in non-stimulating media for up to three days and examined for CD69 
expression on CD8+ T cels. Mean expression ± standard eror is indicated for each 
treatment. Bryostatin-1 treatment at 10 nM and 1 nM and bryostatin-1 (10 
nM)/romidepsin treatment al significantly upregulate CD69 for al four timepoints (p < 
0.0001), as did prostratin treatment (p < 0.001, p < 0.001, p < 0.01, and p < 0.05 at the 
respective timepoints) as calculated by multiple one-way repeated measures ANOVAs. 

































Figure 8. CD3 expression is decreased due to treatment with bryostatin-1, prostratin, and 
the combination of bryostatin-1/romidepsin. Eight HIV-negative donors' PBMCs were 
treated with LRAs for at least 6 h and examined for CD3 expression on CD8+ T cels. A) 
Mean fluorescence intensity (MFI) of CD3 expression in CD8+ T cels treated with drug 
for 6 or 18 h normalized to no treatment. One-way repeated measures ANOVAs were 
used to calculate significance for 6-hour and 18-hour treatments separately. B) Mean 
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fluorescence intensity (MFI) of CD3 expression in CD8+ T cels treated with drug for 6 h 
and then incubated in non-stimulating media for one day afterward normalized to no 
treatment. A one-way repeated measures ANOVA was used to calculate significance. 
The level of significance indicated is in comparison to vehicle (DMSO). * p < 0.05, ** p 






Supplementary Figure 1. Bulk CD8+ T cel expression of PD-1 is upregulated as 
measured by mean fluorescence intensity (MFI). Eight HIV-negative donor PBMCs were 
treated with LRAs for six hours prior to washing and further culture in the presence of 
anti-CD3/CD28 antibodies. A) Gating schematic for PD-1 as measured in Figs. 5 and 6. 
B) Expression of PD-1 as calculated instead by the MFI of PD-1 in treated cels divided 
by the MFI of PD-1 in untreated cels. * p<0.05. 
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